

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C12P 7/26, C12N 5/00, 11/00, 15/63</b>		<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 96/40968</b> <b>(43) International Publication Date:</b> 19 December 1996 (19.12.96)
<b>(21) International Application Number:</b> PCT/US96/09320 <b>(22) International Filing Date:</b> 5 June 1996 (05.06.96) <b>(30) Priority Data:</b> 08/486,645 7 June 1995 (07.06.95) US <b>(71) Applicants:</b> THE LELAND STANFORD JUNIOR UNIVERSITY [US/US]; Suite 350, 900 Welch Road, Palo Alto, CA 94304-1850 (US). THE JOHN INNES CENTRE [GB/GB]; Norwich Research Park, Colney Lane, Norwich NR4 7UH (GB). <b>(72) Inventors:</b> KHOSLA, Chaitan; 132 Peter Coutts Circle, Stanford, CA 94305 (US). HOPWOOD, David, A.; 244 Unthank Road, Norwich NR2 2AH (GB). EBERT-KHOSLA, Suzanne; 132 Peter Coutts Circle, Stanford, CA 94305 (US). McDANIEL, Robert; 2891 Alma Street, No. D, Palo Alto, CA 94306 (US). FU, Hong; Chemical Engineering, Stauffer III, Stanford University, Stanford, CA 94305-5025 (US). KAO, Camilla; 19A Escondido Village, Stanford, CA 94305 (US). <b>(74) Agents:</b> BAROVSKY, Kenneth et al.; Reed & Robins, Suite 200, 285 Hamilton Avenue, Palo Alto, CA 94301 (US).		<b>(81) Designated States:</b> AL, AM, AU, BB, BG, BR, CA, CN, CZ, EE, FI, GE, HU, IL, IS, JP, KG, KP, KR, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>	
<b>(54) Title:</b> RECOMBINANT PRODUCTION OF NOVEL POLYKETIDES			
<b>(57) Abstract</b>  Novel polyketides and novel methods of efficiently producing both new and known polyketides, using recombinant technology, are disclosed. In particular, a novel host-vector system is described which is used to produce polyketide synthases which in turn catalyze the production of a variety of polyketides.			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

5                    RECOMBINANT PRODUCTION OF NOVEL POLYKETIDESDescriptionReference to Government Contract

10                    This invention was made with United States Government support in the form of a grant from the National Science Foundation (BCS-9209901).

Technical Field

15                    The present invention relates generally to polyketides and polyketide synthases. In particular, the invention pertains to the recombinant production of polyketides using a novel host-vector system. In addition, the invention relates to the combinatorial  
20                    biosynthesis of polyketides.

Background of the Invention

                    Polyketides are a large, structurally diverse family of natural products. Polyketides possess a broad  
25                    range of biological activities including antibiotic and pharmacological properties. For example, polyketides are represented by such antibiotics as tetracyclines and erythromycin, anticancer agents including daunomycin, immunosuppressants, for example FK506 and rapamycin, and  
30                    veterinary products such as monensin and avermectin.

                    Polyketides occur in most groups of organisms and are especially abundant in a class of mycelial bacteria, the actinomycetes, which produce various polyketides.

35

Polyketide synthases (PKSs) are multifunctional enzymes related to fatty acid synthases (FASs). PKSs catalyze the biosynthesis of polyketides through repeated (decarboxylative) Claisen condensations between  
5 acylthioesters, usually acetyl, propionyl, malonyl or methylmalonyl. Following each condensation, they introduce structural variability into the product by catalyzing all, part, or none of a reductive cycle comprising a ketoreduction, dehydration, and  
10 enoylreduction on the  $\beta$ -keto group of the growing polyketide chain. PKSs incorporate enormous structural diversity into their products, in addition to varying the condensation cycle, by controlling the overall chain length, choice of primer and extender units and,  
15 particularly in the case of aromatic polyketides, regiospecific cyclizations of the nascent polyketide chain. After the carbon chain has grown to a length characteristic of each specific product, it is released from the synthase by thiolysis or acyltransfer. Thus,  
20 PKSs consist of families of enzymes which work together to produce a given polyketide. It is the controlled variation in chain length, choice of chain-building units, and the reductive cycle, genetically programmed into each PKS, that contributes to the variation seen  
25 among naturally occurring polyketides.

Two general classes of PKSs exist. One class, known as Type I PKSs, is represented by the PKSs for macrolides such as erythromycin. These "complex" or "modular" PKSs include assemblies of several large  
30 multifunctional proteins carrying, between them, a set of separate active sites for each step of carbon chain assembly and modification (Cortes, J. et al. *Nature* (1990) 348:176; Donadio, S. et al. *Science* (1991) 252:675; MacNeil, D.J. et al. *Gene* (1992) 115:119).  
35 Structural diversity occurs in this class from variations

in the number and type of active sites in the PKSs. This class of PKSs displays a one-to-one correlation between the number and clustering of active sites in the primary sequence of the PKS and the structure of the polyketide backbone.

The second class of PKSs, called Type II PKSs, is represented by the synthases for aromatic compounds. Type II PKSs have a single set of iteratively used active sites (Bibb, M.J. et al. *EMBO J.* (1989) 8:2727; Sherman, D.H. et al. *EMBO J.* (1989) 8:2717; Fernandez-Moreno, M.A. et al. *J. Biol. Chem.* (1992) 267:19278).

In contrast, fungal PKSs, such as the 6-methylsalicylic acid PKS, consist of a single multi-domain polypeptide which includes all the active sites required for the biosynthesis of 6-methylsalicylic acid (Beck, J. et al. *Eur. J. Biochem.* (1990) 192:487-498; Davis, R. et al. *Abstr. of the Genetics of Industrial Microorganism Meeting, Montreal, abstr. P288* (1994)).

*Streptomyces* is an actinomycete which is an abundant producer of aromatic polyketides. In each *Streptomyces* aromatic PKS so far studied, carbon chain assembly requires the products of three open reading frames (ORFs). ORF1 encodes a ketosynthase (KS) and an acyltransferase (AT) active site; ORF2 encodes a PKS chain length determining factor (CLF); and ORF3 encodes a discrete acyl carrier protein (ACP).

*Streptomyces coelicolor* produces the blue-pigmented polyketide, actinorhodin. The actinorhodin gene cluster (*act*), has been cloned (Malpartida, F. and Hopwood, D.A. *Nature* (1984) 309:462; Malpartida, F. and Hopwood, D.A. *Mol. Gen. Genet.* (1986) 205:66) and completely sequenced (Fernandez-Moreno, M.A. et al. *J. Biol. Chem.* (1992) 267:19278; Hallam, S.E. et al. *Gene* (1988) 74:305; Fernandez-Moreno, M.A. et al.

Cell (1991) 66:769; Caballero, J. et al. *Mol. Gen. Genet.* (1991) 230:401). The cluster encodes the PKS enzymes described above, a cyclase and a series of tailoring enzymes involved in subsequent modification reactions leading to actinorhodin, as well as proteins involved in export of the antibiotic and at least one protein that specifically activates transcription of the gene cluster. Other genes required for global regulation of antibiotic biosynthesis, as well as for the supply of starter (acetyl CoA) and extender (malonyl CoA) units for polyketide biosynthesis, are located elsewhere in the genome.

The act gene cluster from *S. coelicolor* has been used to produce actinorhodin in *S. parvulus*. Malpartida, F. and Hopwood, D.A. *Nature* (1984) 309:462. Bartel et al. *J. Bacteriol.* (1990) 172:4816-4826, recombinantly produced aloesaponarin II using *S. galilaeus* transformed with an *S. coelicolor* act gene cluster consisting of four genetic loci, actI, actIII, actIV and actVII. Hybrid PKSs, including the basic act gene set but with ACP genes derived from granaticin, oxytetracycline, tetracenomycin and frenolicin PKSs, have also been designed which are able to express functional synthases. Khosla, C. et al. *J. Bacteriol.* (1993) 175:2197-2204. Hopwood, D.A. et al. *Nature* (1985) 314:642-644, describes the production of hybrid polyketides, using recombinant techniques. Sherman, D.H. et al. *J. Bacteriol.* (1992) 174:6184-6190, reports the transformation of various *S. coelicolor* mutants, lacking different components of the act PKS gene cluster, with the corresponding granaticin (gra) genes from *S. violaceoruber*, in trans.

However, no one to date has described the recombinant production of polyketides using genetically

engineered host cells which substantially lack their entire native PKS gene clusters.

Summary of the Invention

5           The present invention provides for novel polyketides and novel methods of efficiently producing both new and known polyketides, using recombinant technology. In particular, a novel host-vector system is used to produce PKSS which in turn catalyze the  
10       production of a variety of polyketides. Furthermore, methods are provided for the combinatorial biosynthesis of polyketide libraries which can be screened for active compounds. Such polyketides are useful as antibiotics, antitumor agents, immunosuppressants and for a wide  
15       variety of other pharmacological purposes.

          Accordingly, in one embodiment, the invention is directed to a genetically engineered cell which expresses a polyketide synthase (PKS) gene cluster in its native, nontransformed state, the genetically engineered  
20       cell substantially lacking the entire native PKS gene cluster.

          In another embodiment, the invention is directed to the genetically engineered cell as described above, wherein the cell comprises:

25           (a) a replacement PKS gene cluster which encodes a PKS capable of catalyzing the synthesis of a polyketide; and

          (b) one or more control sequences operatively linked to the PKS gene cluster, whereby the genes in the  
30       gene cluster can be transcribed and translated in the genetically engineered cell,

          with the proviso that when the replacement PKS gene cluster comprises an entire PKS gene set, at least one of the PKS genes or control elements is heterologous  
35       to the cell.

In particularly preferred embodiments, the genetically engineered cell is *Streptomyces coelicolor*, the cell substantially lacks the entire native actinorhodin PKS gene cluster and the replacement PKS gene cluster comprises a first gene encoding a PKS ketosynthase and a PKS acyltransferase active site (KS/AT), a second gene encoding a PKS chain length determining factor (CLF), and a third gene encoding a PKS acyl carrier protein (ACP).

In another embodiment, the invention is directed to a method for producing a recombinant polyketide comprising:

(a) providing a population of cells as described above; and

(b) culturing the population of cells under conditions whereby the replacement PKS gene cluster present in the cells, is expressed.

In still another embodiment, the invention is directed to a method for producing a recombinant polyketide comprising:

(a) inserting a first portion of a replacement PKS gene cluster into a donor plasmid and inserting a second portion of a replacement PKS gene cluster into a recipient plasmid, wherein the first and second portions collectively encode a complete replacement PKS gene cluster, and further wherein:

i. the donor plasmid expresses a gene which encodes a first selection marker and is capable of replication at a first, permissive temperature and incapable of replication at a second, non-permissive temperature;

ii. the recipient plasmid expresses a gene which encodes a second selection marker; and

iii. the donor plasmid comprises regions of DNA complementary to regions of DNA in the recipient



plasmid, such that homologous recombination can occur between the first portion of the replacement PKS gene cluster and the second portion of the replacement gene cluster, whereby a complete replacement gene cluster can be generated;

(b) transforming the donor plasmid and the recipient plasmid into a host cell and culturing the transformed host cell at the first, permissive temperature and under conditions which allow the growth of host cells which express the first and/or the second selection markers, to generate a first population of cells;

(c) culturing the first population of cells at the second, non-permissive temperature and under conditions which allow the growth of cells which express the first and/or the second selection markers, to generate a second population of cells which includes host cells which contain a recombinant plasmid comprising a complete PKS replacement gene cluster;

(d) transferring the recombinant plasmid from the second population of cells into the genetically engineered cell described above to generate transformed genetically engineered cells; and

(e) culturing the transformed genetically engineered cells under conditions whereby the replacement PKS gene cluster present in the cells is expressed.

In a further embodiment, the invention is drawn to a method for preparing a combinatorial polyketide library comprising:

(a) providing a population of vectors wherein the vectors comprise a random assortment of polyketide synthase (PKS) genes, modules, active sites, or portions thereof and one or more control sequences operatively linked to said genes;

35

(b) transforming a population of host cells with said population of vectors;

(c) culturing said population of host cells under conditions whereby the genes in said gene cluster  
5 can be transcribed and translated, thereby producing a combinatorial library of polyketides.

In still another embodiment, the invention is drawn to a method for producing a combinatorial polyketide library comprising:

10 a) providing one or more expression plasmids containing a random assortment of 1 or more first modules of a modular PKS gene cluster wherein the expression plasmids express a gene which encodes a first selection marker;

15 b) providing a pool of donor plasmids containing a random assortment of second modules of a modular PKS gene cluster wherein the donor plasmids express a gene which encodes a second selection marker and further wherein the donor plasmids comprise regions  
20 of DNA complementary to regions of DNA in the expression plasmids, such that homologous recombination can occur between the first and second modules;


c) transforming the expression plasmids and the donor plasmids into a first population of host cells  
25 to produce a first pool of transformed host cells;

d) culturing the first pool of transformed host cells under conditions which allow homologous recombination to occur between the first and second modules to produce recombined plasmids comprising  
30 recombined PKS gene cluster modules;

e) transferring the recombined plasmids into a second population of host cells to generate a second pool of transformed host cells; and

f) culturing the second pool of transformed host cells under conditions whereby the combinatorial polyketide library is produced.

In yet another embodiment, the invention is directed to a polyketide compound having the structural formula (I)



wherein:

$R^1$  is selected from the group consisting of hydrogen and lower alkyl and  $R^2$  is selected from the group consisting of hydrogen, lower alkyl and lower alkyl ester, or wherein  $R^1$  and  $R^2$  together form a lower alkylene bridge optionally substituted with one to four hydroxyl or lower alkyl groups;


$R^3$  and  $R^5$  are independently selected from the group consisting of hydrogen, halogen, lower alkyl, lower alkoxy, amino, lower alkyl mono- or di-substituted amino and nitro;

$R^4$  is selected from the group consisting of halogen, lower alkyl, lower alkoxy, amino, lower alkyl mono- or di-substituted amino and nitro;


$R^6$  is selected from the group consisting of hydrogen, lower alkyl, and  $-CHR^7-(CO)R^8$  where  $R^7$  and  $R^8$  are independently selected from the group consisting of hydrogen and lower alkyl; and

5  $i$  is 1, 2 or 3.

In another embodiment, the invention related to novel polyketides having the structures



SEK4 (12)




SEK15 (13)

35

5

10




15

RM20b (14)

20

25




30

RM20c (15)

or

35




SEK15b (16)

15

20

In another embodiment, the invention is directed to a polyketide compound formed by catalytic cyclization of an enzyme-bound ketide having the structure (II)

25



wherein:


$R^{11}$  is selected from the group consisting of methyl,  $-\text{CH}_2(\text{CO})\text{CH}_3$  and  $-\text{CH}_2(\text{CO})\text{CH}_2(\text{CO})\text{CH}_3$ ;

$R^{12}$  is selected from the group consisting of  
 5  $-\text{S}-\text{E}$  and  $-\text{CH}_2(\text{CO})-\text{S}-\text{E}$ , wherein E represents a polyketide synthase produced by the genetically engineered cells above; and

one of  $R^{13}$  and  $R^{14}$  is hydrogen and the other is hydroxyl, or  $R^{13}$  and  $R^{14}$  together represent carbonyl.

10 In still another embodiment, the invention is directed to a method for producing an aromatic polyketide, comprising effecting cyclization of an enzyme-bound ketide having the structure (II), wherein cyclization is induced by the polyketide synthase.

15 In a further embodiment, the invention is directed to a polyketide compound having the structural formula (III)




wherein  $R^2$  and  $R^4$  are as defined above and  $i$  is 0, 1 or 2.

35 In another embodiment, the invention is directed to a polyketide compound having the structural formula (IV)

5

10




15

wherein  $R^2$ ,  $R^4$  and  $i$  are as defined above for structural formula (III).

In still another embodiment, the invention is directed to a polyketide compound having the structural formula (V)

20

25



30

wherein  $R^2$ ,  $R^4$  and  $i$  are as defined above for structural formula (III).

35



These and other embodiments of the subject invention will readily occur to those of ordinary skill in the art in view of the disclosure herein.

5     Brief Description of the Figures

Figure 1A shows the gene clusters for *act*, *gra*, and *tcm* PKSs and cyclases. Figure 1B shows the gene clusters for *act*, *tcm*, *fren*, *gris*, and *whiE* PKSs and cyclases.

10     Figure 2 shows the strategy for making *S. coelicolor* CH999. Figure 2A depicts the structure of the *act* gene cluster present on the *S. coelicolor* CH1 chromosome. Figure 2B shows the structure of pLRemEts and Figure 2C shows the portion of the CH999 chromosome  
15     with the *act* gene cluster deleted.

Figure 3 is a diagram of plasmid pRM5.

Figure 4 schematically illustrates formation of aloesaponarin II (2) and its carboxylated analog, 3,8-dihydroxy-1-methylanthraquinone-2-carboxylic acid (1) as  
20     described in Example 3.

Figure 5 provides the structures of actinorhodin (3), granaticin (4), tetracenomycin (5) and mutactin (6), referenced in Example 4.

Figure 6 schematically illustrates the  
25     preparation, via cyclization of the polyketide precursors, of aloesaponarin II (2), its carboxylated analog, 3,8-dihydroxy-1-methylanthraquinone-2-carboxylic acid (1), tetracenomycin (5) and new compound RM20 (9), as explained in Example 4, part (A).

30     Figure 7 schematically illustrates the preparation, via cyclization of the polyketide precursors, of frenolicin (7), nanomycin (8) and actinorhodin (3).

Figure 8 schematically illustrates the  
35     preparation, via cyclization of the polyketide

precursors, of novel compounds RM20 (9), RM18 (10), RM18b (11), SEK4 (12), SEK15 (13), RM20b (14), RM20c (15) and SEK15b (16).

5 Figure 9 depicts the genetic model for the 6-deoxyerythronolide B synthase (DEBS).

Figure 10 is a representation of the overall biosynthetic pathway for a typical polyketide natural product.

10 Figure 11 shows the structures of various polyketide of aromatic, modular and fungal PKSs.

Figure 12 is a scheme for rationally engineered biosynthesis of polyketides.

15 Figure 13 shows the common moieties observed in engineered polyketides formed by non-enzymatic reactions involving the uncyclized portions of the carbon chain. Hemiketals (a) and benzene rings (b) are formed at the methyl ends, whereas  $\gamma$ -pyrone rings (c) and decarboxylations (d) occur at the carboxyl ends. The two chain ends can also co-cyclize via aldol condensations (e).

20 Figure 14 illustrates the structures and proposed pathways of octaketide-derived polyketides biosynthesis including RM77 (19).

25 Figure 15 illustrates the structures and proposed pathways of decaketide-derived polyketides biosynthesis including RM80 (20) and RM80b (21).

30 Figure 16 shows the structures of SEK34 (22) the two novel polyketides SEK43 (23) and SEK26 (24) and other polyketides produced by genetic engineering in *S. coelicolor* CH999.

Figure 17 is a diagram of the proposed biosynthetic pathways for the rationally designed polyketides SEK43 (23) and SEK26 (24).

35 Figure 18 shows the strategy for the construction of recombinant modular PKSs.

Figure 19 is a diagram of plasmid pCK7.

Figure 20 schematically illustrates the preparation of 6-deoxyerythromolide B (17) from propionate and 8,8a-deoxyoleandolide (18) from an acetate starter.

Figure 21A shows the biosynthesis of (2R,3S,4S,5R)-2,4-dimethyl-3,5-dihydroxy-n-heptanoic acid  $\delta$ -lactone (25) by DEBS1 in *S. coelicolor* CH999. Figure 21B shows the biosynthesis of (25) and

(2R,3S,4S,5R)-2,4-dimethyl-3,5-dihydroxy-n-hexanoic acid  $\delta$ -lactone (26) by the "1+2+TE" PKS in *S. coelicolor* CH999. The vertical line between ACP-2 and the TE represents the fusion junction in this deletion mutant.

Figure 22 shows the biosynthesis of (8R,9S)-8,9-dihydro-8-methyl-9-hydroxy-10-deoxymethonolide (27) by the "1+2+3+4+5+TE" PKS in *S. coelicolor* CH999. The vertical line between KR-5 and ACP-6 represents the fusion junction in this deletion mutant.

#### Detailed Description of the Invention

The practice of the present invention will employ, unless otherwise indicated, conventional methods of chemistry, microbiology, molecular biology and recombinant DNA techniques within the skill of the art. Such techniques are explained fully in the literature. See, e.g., Sambrook, et al. *Molecular Cloning: A Laboratory Manual* (Current Edition); *DNA Cloning: A Practical Approach*, vol. I & II (D. Glover, ed.); *Oligonucleotide Synthesis* (N. Gait, ed., Current Edition); *Nucleic Acid Hybridization* (B. Hames & S. Higgins, eds., Current Edition); *Transcription and Translation* (B. Hames & S. Higgins, eds., Current Edition).

All publications, patents and patent applications cited herein, whether *supra* or *infra*, are hereby incorporated by reference in their entirety.

As used in this specification and the appended  
5 claims, the singular forms "a," "an" and "the" include plural references unless the content clearly dictates otherwise. Thus, reference to "a polyketide" includes mixtures of polyketides, reference to "a polyketide synthase" includes mixtures of polyketide synthases, and  
10 the like.

#### A. Definitions

In describing the present invention, the following terms will be employed, and are intended to be  
15 defined as indicated below.

By "replacement PKS gene cluster" is meant any set of PKS genes capable of producing a functional PKS when under the direction of one or more compatible control elements, as defined below, in a host cell  
20 transformed therewith. A functional PKS is one which catalyzes the synthesis of a polyketide. The term "replacement PKS gene cluster" encompasses one or more genes encoding for the various proteins necessary to catalyze the production of a polyketide. A "replacement  
25 PKS gene cluster" need not include all of the genes found in the corresponding cluster in nature. Rather, the gene cluster need only encode the necessary PKS components to catalyze the production of an active polyketide. Thus, as explained further below, if the gene cluster includes,  
30 for example, eight genes in its native state and only three of these genes are necessary to provide an active polyketide, only these three genes need be present. Furthermore, the cluster can include PKS genes derived from a single species, or may be hybrid in nature with,  
35 e.g., a gene derived from a cluster for the synthesis of

a particular polyketide replaced with a corresponding gene from a cluster for the synthesis of another polyketide. Hybrid clusters can include genes derived from both Type I and Type II PKSs. As explained above, Type I PKSs include several large multifunctional proteins carrying, between them, a set of separate active sites for each step of carbon chain assembly and modification. Type II PKSs, on the other hand, have a single set of iteratively used active sites. These classifications are well known. See, e.g., Hopwood, D.A. and Khosla, C. *Secondary metabolites: their function and evolution* (1992) Wiley Chichester (Ciba Foundation Symposium 171) p 88-112; Bibb, M.J. et al. *EMBO J.* (1989) 8:2727; Sherman, D.H. et al. *EMBO J.* (1989) 8:2717; Fernandez-Moreno, M.A. et al. *J. Biol. Chem.* (1992) 267:19278; Cortes, J. et al. *Nature* (1990) 348:176; Donadio, S. et al. *Science* (1991) 252:675; MacNeil, D.J. et al. *Gene* (1992) 115:119. Hybrid clusters are exemplified herein and are described further below. The genes included in the gene cluster need not be the native genes, but can be mutants or analogs thereof. Mutants or analogs may be prepared by the deletion, insertion or substitution of one or more nucleotides of the coding sequence. Techniques for modifying nucleotide sequences, such as site-directed mutagenesis, are described in, e.g., Sambrook et al., *supra*; *DNA Cloning*, Vols. I and II, *supra*; *Nucleic Acid Hybridization*, *supra*.

A "replacement PKS gene cluster" may also contain genes coding for modifications to the core polyketide catalyzed by the PKS, including, for example, genes encoding post-polyketide synthesis enzymes derived from natural products pathways such as O-methyltransferases and glycosyltransferases. A "replacement PKS gene cluster" may further include genes encoding hydroxylases, methylases or other alkylases, oxidases,

reductases, glycotransferases, lyases, ester or amide synthases, and various hydrolases such as esterases and amidases.

5 As explained further below, the genes included in the replacement gene cluster need not be on the same plasmid or if present on the same plasmid, can be controlled by the same or different control sequences.

A "library" or "combinatorial library" of polyketides is intended to mean a collection of  
10 polyketides catalytically produced by a PKS gene cluster capable of catalyzing the synthesis of a polyketide. The library can be produced by a PKS gene cluster that contains any combination of native, homolog or mutant genes from aromatic, modular or fungal PKSs. The  
15 combination of genes can be derived from a single PKS gene cluster, e.g., *act*, *fren*, *gra*, *tcm*, *whiE*, *gris*, *ery*, or the like, and may optionally include genes encoding tailoring enzymes which are capable of catalyzing the further modification of a polyketide. Alternatively, the  
20 combination of genes can be rationally or stochastically derived from an assortment of PKS gene clusters, e.g. a minimal PKS gene cluster can be constructed to contain the KS/AT component from an *act* PKS, the CLF component from a *tcm* PKS and a ACP component from a *fren* PKS. The  
25 combination of genes can optionally include KR, CYC and ARO components of PKS gene clusters as well. The library of polyketides thus produced can be tested or screened for biological, pharmacological or other activity.

By "random assortment" is intended any  
30 combination and/or order of genes, homologs or mutants which encode for the various PKS enzymes, modules, active sites or portions thereof derived from aromatic, modular or fungal PKS gene clusters.

By "genetically engineered host cell" is meant  
35 a host cell where the native PKS gene cluster has been

deleted using recombinant DNA techniques or host cell into which a heterologous PKS gene cluster has been inserted. Thus, the term would not encompass mutational events occurring in nature. A "host cell" is a cell  
5 derived from a procaryotic microorganism or a eucaryotic cell line cultured as a unicellular entity, which can be, or has been, used as a recipient for recombinant vectors bearing the PKS gene clusters of the invention. The term includes the progeny of the original cell which has been  
10 transfected. It is understood that the progeny of a single parental cell may not necessarily be completely identical in morphology or in genomic or total DNA complement to the original parent, due to accidental or deliberate mutation. Progeny of the parental cell which  
15 are sufficiently similar to the parent to be characterized by the relevant property, such as the presence of a nucleotide sequence encoding a desired PKS, are included in the definition, and are covered by the above terms.

20 The term "heterologous" as it relates to nucleic acid sequences such as coding sequences and control sequences, denotes sequences that are not normally associated with a region of a recombinant construct, and/or are not normally associated with a  
25 particular cell. Thus, a "heterologous" region of a nucleic acid construct is an identifiable segment of nucleic acid within or attached to another nucleic acid molecule that is not found in association with the other molecule in nature. For example, a heterologous region  
30 of a construct could include a coding sequence flanked by sequences not found in association with the coding sequence in nature. Another example of a heterologous coding sequence is a construct where the coding sequence itself is not found in nature (e.g., synthetic sequences  
35 having codons different from the native gene).

Similarly, a host cell transformed with a construct which is not normally present in the host cell would be considered heterologous for purposes of this invention. Allelic variation or naturally occurring mutational events do not give rise to heterologous DNA, as used herein.

A "coding sequence" or a sequence which "encodes" a particular PKS, is a nucleic acid sequence which is transcribed (in the case of DNA) and translated (in the case of mRNA) into a polypeptide *in vitro* or *in vivo* when placed under the control of appropriate regulatory sequences. The boundaries of the coding sequence are determined by a start codon at the 5' (amino) terminus and a translation stop codon at the 3' (carboxy) terminus. A coding sequence can include, but is not limited to, cDNA from procaryotic or eucaryotic mRNA, genomic DNA sequences from procaryotic or eucaryotic DNA, and even synthetic DNA sequences. A transcription termination sequence will usually be located 3' to the coding sequence.

A "nucleic acid" sequence can include, but is not limited to, procaryotic sequences, eucaryotic mRNA, cDNA from eucaryotic mRNA, genomic DNA sequences from eucaryotic (e.g., mammalian) DNA, and even synthetic DNA sequences. The term also captures sequences that include any of the known base analogs of DNA and RNA such as, but not limited to 4-acetylcytosine, 8-hydroxy-N6-methyladenosine, aziridinylcytosine, pseudoisocytosine, 5-(carboxyhydroxymethyl) uracil, 5-fluorouracil, 5-bromouracil, 5-carboxymethylaminomethyl-2-thiouracil, 5-carboxymethylaminomethyluracil, dihydrouracil, inosine, N6-isopentenyladenine, 1-methyladenine, 1-methylpseudo-uracil, 1-methylguanine, 1-methylinosine, 2,2-dimethyl-guanine, 2-methyladenine, 2-methylguanine, 3-methyl-cytosine, 5-methylcytosine, N6-methyladenine,



7-methylguanine, 5-methylaminomethyluracil, 5-methoxy-aminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarbonylmethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid, oxybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, N-uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid, pseudouracil, queosine, 2-thiocytosine, and 2,6-diaminopurine. A transcription termination sequence will usually be located 3' to the coding sequence.

DNA "control sequences" refers collectively to promoter sequences, ribosome binding sites, polyadenylation signals, transcription termination sequences, upstream regulatory domains, enhancers, and the like, which collectively provide for the transcription and translation of a coding sequence in a host cell. Not all of these control sequences need always be present in a recombinant vector so long as the desired gene is capable of being transcribed and translated.

"Operably linked" refers to an arrangement of elements wherein the components so described are configured so as to perform their usual function. Thus, control sequences operably linked to a coding sequence are capable of effecting the expression of the coding sequence. The control sequences need not be contiguous with the coding sequence, so long as they function to direct the expression thereof. Thus, for example, intervening untranslated yet transcribed sequences can be present between a promoter sequence and the coding sequence and the promoter sequence can still be considered "operably linked" to the coding sequence.

By "selection marker" is meant any genetic marker which can be used to select a population of cells

which carry the marker in their genome. Examples of selection markers include: auxotrophic markers by which cells are selected by their ability to grow on minimal media with or without a nutrient or supplement, e.g., thymidine, diaminopimelic acid or biotin; metabolic markers by which cells are selected for their ability to grow on minimal media containing the appropriate sugar as the sole carbon source or the ability of cells to form colored colonies containing the appropriate dyes or chromogenic substrates; and drug resistance markers by which cells are selected by their ability to grow on media containing one or more of the appropriate drugs, e.g., tetracycline, ampicillin, kanamycin, streptomycin or nalidixic acid.

"Recombination" is a the reassortment of sections of DNA sequences between two DNA molecules. "Homologous recombination" occurs between two DNA molecules which hybridize by virtue of homologous or complementary nucleotide sequences present in each DNA molecule.

The term "alkyl" as used herein refers to a branched or unbranched saturated hydrocarbon group of 1 to 24 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, octyl, decyl, tetradecyl, hexadecyl, eicosyl, tetracosyl and the like. Preferred alkyl groups herein contain 1 to 12 carbon atoms. The term "lower alkyl" intends an alkyl group of one to six carbon atoms, preferably one to four carbon atoms.

The term "alkylene" as used herein refers to a difunctional saturated branched or unbranched hydrocarbon chain containing from 1 to 24 carbon atoms, and includes, for example, methylene ( $-\text{CH}_2-$ ), ethylene ( $-\text{CH}_2-\text{CH}_2-$ ), propylene ( $-\text{CH}_2-\text{CH}_2-\text{CH}_2-$ ), 2-methylpropylene [ $-\text{CH}_2-\text{CH}(\text{CH}_3)-\text{CH}_2-$ ], hexylene [ $-(\text{CH}_2)_6-$ ] and the like. "Lower

alkylene" refers to an alkylene group of 1 to 6, more preferably 1 to 4, carbon atoms.

The term "alkoxy" as used herein intends an alkyl group bound through a single, terminal ether linkage; that is, an "alkoxy" group may be defined as -OR where R is alkyl as defined above. A "lower alkoxy" group intends an alkoxy group containing one to six, more preferably one to four, carbon atoms.

"Halo" or "halogen" refers to fluoro, chloro, bromo or iodo, and usually relates to halo substitution for a hydrogen atom in an organic compound. Of the halos, chloro and fluoro are generally preferred.

"Optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where said event or circumstance occurs and instances where it does not. For example, the phrase "optionally substituted alkylene" means that an alkylene moiety may or may not be substituted and that the description includes both unsubstituted alkylene and alkylene where there is substitution.

#### B. General Methods

Central to the present invention is the discovery of a host-vector system for the efficient recombinant production of both novel and known polyketides. In particular, the invention makes use of genetically engineered cells which have their naturally occurring PKS genes substantially deleted. These host cells can be transformed with recombinant vectors, encoding a variety of PKS gene clusters, for the production of active polyketides. The invention provides for the production of significant quantities of product at an appropriate stage of the growth cycle. The polyketides so produced can be used as therapeutic

agents, to treat a number of disorders, depending on the type of polyketide in question. For example, several of the polyketides produced by the present method will find use as immunosuppressants, as anti-tumor agents, as well  
5 as for the treatment of viral, bacterial and parasitic infections. The ability to recombinantly produce polyketides also provides a powerful tool for characterizing PKSs and the mechanism of their actions.

More particularly, host cells for the  
10 recombinant production of the subject polyketides can be derived from any organism with the capability of harboring a recombinant PKS gene cluster. Thus, the host cells of the present invention can be derived from either procaryotic or eucaryotic organisms. However, preferred  
15 host cells are those constructed from the actinomycetes, a class of mycelial bacteria which are abundant producers of a number of polyketides. A particularly preferred genus for use with the present system is *Streptomyces*. Thus, for example, *S. ambofaciens*, *S. avermitilis*, *S.*  
20 *azureus*, *S. cinnamomensis*, *S. coelicolor*, *S. curacoi*, *S. erythraeus*, *S. fradiae*, *S. galilaeus*, *S. glaucescens*, *S. hygroscopicus*, *S. lividans*, *S. parvulus*, *S. peucetius*, *S. rimosus*, *S. roseofulvus*, *S. thermotolerans*, *S.*  
*violaceoruber*, among others, will provide convenient host  
25 cells for the subject invention, with *S. coelicolor* being preferred. (See, e.g., Hopwood, D.A. and Sherman, D.H. *Ann. Rev. Genet.* (1990) 24:37-66; O'Hagan, D. *The Polyketide Metabolites* (Ellis Horwood Limited, 1991), for a description of various polyketide-producing organisms  
30 and their natural products.)

The above-described cells are genetically engineered by deleting the naturally occurring PKS genes therefrom, using standard techniques, such as by homologous recombination. (See, e.g., Khosla, C. et al.  
35 *Molec. Microbiol.* (1992) 6:3237). Exemplified herein is

a genetically engineered *S. coelicolor* host cell. Native strains of *S. coelicolor* produce a PKS which catalyzes the biosynthesis of the aromatic polyketide actinorhodin (structure 3, Figure 5). The novel strain, *S. coelicolor* CH999 (as described in the examples), was constructed by deleting, via homologous recombination, the entire natural act cluster from the chromosome of *S. coelicolor* CH1 (Figure 2) (Khosla, C. *Molec. Microbiol.* (1992) 6:3237), a strain lacking endogenous plasmids and carrying a stable mutation that blocks biosynthesis of another pigmented *S. coelicolor* antibiotic, undecylprodigiosin.

The host cells described above can be transformed with one or more vectors, collectively encoding a functional PKS set, or a cocktail comprising a random assortment of PKS genes, modules, active sites, or portions thereof. The vector(s) can include native or hybrid combinations of PKS subunits or cocktail components, or mutants thereof. As explained above, the replacement gene cluster need not correspond to the complete native gene cluster but need only encode the necessary PKS components to catalyze the production of a polyketide. For example, in each *Streptomyces* aromatic PKS so far studied, carbon chain assembly requires the products of three open reading frames (ORFs). ORF1 encodes a ketosynthase (KS) and an acyltransferase (AT) active site (KS/AT); as elucidated herein, ORF2 encodes a chain length determining factor (CLF), a protein similar to the ORF1 product but lacking the KS and AT motifs; and ORF3 encodes a discrete acyl carrier protein (ACP). Some gene clusters also code for a ketoreductase (KR) and a cyclase, involved in cyclization of the nascent polyketide backbone. (See Figures 1A and 1B for schematic representations of six PKS gene clusters.) However, it has been found that only the KS/AT, CLF, and

ACP, need be present in order to produce an identifiable polyketide. Thus, in the case of aromatic PKSs derived from *Streptomyces*, these three genes, without the other components of the native clusters, can be included in one  
5 or more recombinant vectors, to constitute a "minimal" replacement PKS gene cluster.

Furthermore, the recombinant vector(s) can include genes from a single PKS gene cluster, or may comprise hybrid replacement PKS gene clusters with, e.g.,  
10 a gene for one cluster replaced by the corresponding gene from another gene cluster. For example, it has been found that ACPs are readily interchangeable among different synthases without an effect on product structure. Furthermore, a given KR can recognize and  
15 reduce polyketide chains of different chain lengths. Accordingly, these genes are freely interchangeable in the constructs described herein. Thus, the replacement clusters of the present invention can be derived from any combination of PKS gene sets which ultimately function to  
20 produce an identifiable polyketide.

Examples of hybrid replacement clusters include clusters with genes derived from two or more of the act gene cluster, the *whiE* gene cluster, frenolicin (*fren*), granaticin (*gra*), tetracenomycin (*tcm*), 6-methylsalicylic  
25 acid (*6-msas*), oxytetracycline (*otc*), tetracycline (*tet*), erythromycin (*ery*), griseusin (*gris*), nanaomycin, medermycin, daunorubicin, tylosin, carbomycin, spiramycin, avermectin, monensin, nonactin, curamycin, rifamycin and candicidin synthase gene clusters, among  
30 others. (For a discussion of various PKSs, see, e.g., Hopwood, D.A. and Sherman, D.H. *Ann. Rev. Genet.* (1990) 24:37-66; O'Hagan, D. *The Polyketide Metabolites* (Ellis Horwood Limited, 1991).)

More particularly, a number of hybrid gene  
35 clusters have been constructed herein, having components

derived from the *act*, *fren*, *tcm*, *gris* and *gra* gene clusters, as depicted in Tables 1, 2, 5 and 6. Several of the hybrid clusters were able to functionally express both novel and known polyketides in *S. coelicolor* CH999 (described above). However, other hybrid gene clusters, as described above, can easily be produced and screened using the disclosure herein, for the production of identifiable polyketides.

Furthermore, a library of randomly cloned ORF1, ORF2, ORF3 and homologs or mutant thereof, as well as other PKS genes and homologs or mutants thereof including ketoreductases, cyclases and aromatases from a collection of aromatic PKS gene clusters, could be constructed and screened for identifiable polyketides using methods described and exemplified herein. In addition, a considerable degree of variability exists for both the starter units (e.g., acetyl CoA, malonyl CoA, propionyl CoA, acetate, butyrate, isobutyrate and the like) and the extender units among certain naturally occurring aromatic PKs; thus, these units can also be used for obtaining novel polyketides via genetic engineering.

Additionally, a library of randomly cloned open reading frames or homologs from a collection of modular PKS gene clusters could be constructed and screened for identifiable polyketides. Such gene clusters are described in further detail below. Recombinant vectors can optionally include genes from an aromatic and a modular PKS gene cluster.

The recombinant vectors, harboring the gene clusters or random assortment of PKS genes, modules, active sites or portions thereof described above, can be conveniently generated using techniques known in the art. For example, the PKS subunits of interest can be obtained from an organism that expresses the same, using recombinant methods, such as by screening cDNA or genomic

libraries, derived from cells expressing the gene, or by deriving the gene from a vector known to include the same. The gene can then be isolated and combined with other desired PKS subunits, using standard techniques.

5 If the gene in question is already present in a suitable expression vector, it can be combined *in situ*, with, e.g., other PKS subunits, as desired. The gene of interest can also be produced synthetically, rather than cloned. The nucleotide sequence can be designed with the

10 appropriate codons for the particular amino acid sequence desired. In general, one will select preferred codons for the intended host in which the sequence will be expressed. The complete sequence can be assembled from overlapping oligonucleotides prepared by standard methods

15 and assembled into a complete coding sequence. See, e.g., Edge (1981) *Nature* 292:756; Nambair et al. (1984) *Science* 223:1299; Jay et al. (1984) *J. Biol. Chem.* 259:6311.

Mutations can be made to the native PKS subunit

20 sequences and such mutants used in place of the native sequence, so long as the mutants are able to function with other PKS subunits to collectively catalyze the synthesis of an identifiable polyketide. Such mutations can be made to the native sequences using conventional

25 techniques such as by preparing synthetic oligonucleotides including the mutations and inserting the mutated sequence into the gene encoding a PKS subunit using restriction endonuclease digestion. (See, e.g., Kunkel, T.A. *Proc. Natl. Acad. Sci. USA* (1985) 82:448; Geisselsoder et al. *BioTechniques* (1987) 5:786.)

30 Alternatively, the mutations can be effected using a mismatched primer (generally 10-20 nucleotides in length) which hybridizes to the native nucleotide sequence (generally cDNA corresponding to the RNA sequence), at a

35 temperature below the melting temperature of the



mismatched duplex. The primer can be made specific by keeping primer length and base composition within relatively narrow limits and by keeping the mutant base centrally located. Zoller and Smith, *Methods Enzymol.* 5 (1983) 100:468. Primer extension is effected using DNA polymerase, the product cloned and clones containing the mutated DNA, derived by segregation of the primer extended strand, selected. Selection can be accomplished using the mutant primer as a hybridization probe. The 10 technique is also applicable for generating multiple point mutations. See, e.g., Dalbie-McFarland et al. *Proc. Natl. Acad. Sci USA* (1982) 79:6409. PCR mutagenesis will also find use for effecting the desired mutations.

15 Random mutagenesis of the nucleotide sequences obtained as described above can be accomplished by several different techniques known in the art, such as by altering sequences within restriction endonuclease sites, inserting an oligonucleotide linker randomly into a 20 plasmid, by irradiation with X-rays or ultraviolet light, by incorporating incorrect nucleotides during *in vitro* DNA synthesis, by error-prone PCR mutagenesis, by preparing synthetic mutants or by damaging plasmid DNA *in vitro* with chemicals. Chemical mutagens include, for 25 example, sodium bisulfite, nitrous acid, hydroxylamine, agents which damage or remove bases thereby preventing normal base-pairing such as hydrazine or formic acid, analogues of nucleotide precursors such as nitrosoguanidine, 5-bromouracil, 2-aminopurine, or 30 acridine intercalating agents such as proflavine, acriflavine, quinacrine, and the like. Generally, plasmid DNA or DNA fragments are treated with chemicals, transformed into *E. coli* and propagated as a pool or library of mutant plasmids.

35

Large populations of random enzyme variants can be constructed *in vivo* using "recombination-enhanced mutagenesis." This method employs two or more pools of, for example,  $10^6$  mutants each of the wild-type encoding nucleotide sequence that are generated using any  
5 convenient mutagenesis technique, described more fully above, and then inserted into cloning vectors.

Once the mutant sequences are generated, the DNA is inserted into an appropriate cloning vector, using  
10 techniques well known in the art (see, e.g., Sambrook et al., *supra*). The choice of vector depends on the pool of mutant sequences, i.e., donor or recipient, with which they are to be employed. Furthermore, the choice of vector determines the host cell to be employed in  
15 subsequent steps of the claimed method. Any transducible cloning vector can be used as a cloning vector for the donor pool of mutants. It is preferred, however, that phagemids, cosmids, or similar cloning vectors be used for cloning the donor pool of mutant encoding nucleotide  
20 sequences into the host cell. Phagemids and cosmids, for example, are advantageous vectors due to the ability to insert and stably propagate therein larger fragments of DNA than in M13 phage and  $\lambda$  phage, respectively. Phagemids which will find use in this method generally  
25 include hybrids between plasmids and filamentous phage cloning vehicles. Cosmids which will find use in this method generally include  $\lambda$  phage-based vectors into which *cos* sites have been inserted. Recipient pool cloning vectors can be any suitable plasmid. The cloning vectors  
30 into which pools of mutants are inserted may be identical or may be constructed to harbor and express different genetic markers (see, e.g., Sambrook et al., *supra*). The utility of employing such vectors having different marker genes may be exploited to facilitate a determination of  
35 successful transduction.

Thus, for example, the cloning vector employed may be a phagemid and the host cell may be *E. coli*. Upon infection of the host cell which contains a phagemid, single-stranded phagemid DNA is produced, packaged and extruded from the cell in the form of a transducing phage in a manner similar to other phage vectors. Thus, clonal amplification of mutant encoding nucleotide sequences carried by phagemids is accomplished by propagating the phagemids in a suitable host cell.

Following clonal amplification, the cloned donor pool of mutants is infected with a helper phage to obtain a mixture of phage particles containing either the helper phage genome or phagemids mutant alleles of the wild-type encoding nucleotide sequence.

Infection, or transfection, of host cells with helper phage is generally accomplished by methods well known in the art (see, e.g., Sambrook et al., *supra*; and Russell et al. (1986) *Gene* 45:333-338).

The helper phage may be any phage which can be used in combination with the cloning phage to produce an infective transducing phage. For example, if the cloning vector is a cosmid, the helper phage will necessarily be a  $\lambda$  phage. Preferably, the cloning vector is a phagemid and the helper phage is a filamentous phage, and preferably phage M13.

If desired after infecting the phagemid with helper phage and obtaining a mixture of phage particles, the transducing phage can be separated from helper phage based on size differences (Barnes et al. (1983) *Methods Enzymol.* 101:98-122), or other similarly effective technique.

The entire spectrum of cloned donor mutations can now be transduced into clonally amplified recipient cells into which has been transduced or transformed a pool of mutant encoding nucleotide sequences. Recipient

cells which may be employed in the method disclosed and claimed herein may be, for example, *E. coli*, or other bacterial expression systems which are not recombination deficient. A recombination deficient cell is a cell in which recombinatorial events is greatly reduced, such as the *rec<sup>-</sup>* mutants of *E. coli* (see, Clark et al. (1965) *Proc. Natl. Acad. Sci. USA* 53:451-459).

By maintaining a high multiplicity of infection (MOI) and a ratio of [transductant forming units (tfu)] : [plaque forming units (pfu)] greater than 1, one can insure that virtually every recipient cell receives at least one mutant gene from the donor pool. The MOI is adjusted by manipulating the ratio of transducing particles to cell density. By the term "high multiplicity of infection" is meant a multiplicity of infection of greater than 1, preferably between 1 to 100, more preferably between 1 and 10.

It is preferred that the tfu:pfu ratio, as reflecting the ratio of transducing phages to helper phages, be as large as possible, at least greater than one, more preferably greater than 100 or more. By exercising the option to separate transducing phage from helper phage, as described above, the tfu:pfu ratio can be maximized.

These transductants can now be selected for the desired expressed protein property or characteristic and, if necessary or desirable, amplified. Optionally, if the phagemids into which each pool of mutants is cloned are constructed to express different genetic markers, as described above, transductants may be selected by way of their expression of both donor and recipient plasmid markers.

The recombinants generated by the above-described methods can then be subjected to selection or

35

screening by any appropriate method, for example, enzymatic or other biological activity.

The above cycle of amplification, infection, transduction, and recombination may be repeated any number of times using additional donor pools cloned on phagemids. As above, the phagemids into which each pool of mutants is cloned may be constructed to express a different marker gene. Each cycle could increase the number of distinct mutants by up to a factor of  $10^6$ . Thus, if the probability of occurrence of an inter-allelic recombination event in any individual cell is  $f$  (a parameter that is actually a function of the distance between the recombining mutations), the transduced culture from two pools of  $10^6$  allelic mutants will express up to  $10^{12}$  distinct mutants in a population of  $10^{12}/f$  cells.

The gene sequences, native or mutant, which collectively encode a replacement PKS gene cluster, can be inserted into one or more expression vectors, using methods known to those of skill in the art. In order to incorporate a random assortment of PKS genes, modules, active sites or portions thereof into an expression vector, a cocktail of same can be prepared and used to generate the expression vector by techniques well known in the art and described in detail below. Expression vectors will include control sequences operably linked to the desired PKS coding sequence. Suitable expression systems for use with the present invention include systems which function in eucaryotic and procaryotic host cells. However, as explained above, procaryotic systems are preferred, and in particular, systems compatible with *Streptomyces spp.* are of particular interest. Control elements for use in such systems include promoters, optionally containing operator sequences, and ribosome binding sites. Particularly useful promoters include

control sequences derived from PKS gene clusters which result in the production of polyketides as secondary metabolites, such as one or more act promoters, *tcm* promoters, spiramycin promoters, and the like. However, 5 other bacterial promoters, such as those derived from sugar metabolizing enzymes, such as galactose, lactose (*lac*) and maltose, will also find use in the present constructs. Additional examples include promoter sequences derived from biosynthetic enzymes such as 10 tryptophan (*trp*), the  $\beta$ -lactamase (*bla*) promoter system, bacteriophage lambda PL, and T5. In addition, synthetic promoters, such as the *tac* promoter (U.S. Patent No. 4,551,433), which do not occur in nature also function in bacterial host cells.

15 Other regulatory sequences may also be desirable which allow for regulation of expression of the PKS replacement sequences relative to the growth of the host cell. Regulatory sequences are known to those of skill in the art, and examples include those which cause 20 the expression of a gene to be turned on or off in response to a chemical or physical stimulus, including the presence of a regulatory compound. Other types of regulatory elements may also be present in the vector, for example, enhancer sequences.

25 Selectable markers can also be included in the recombinant expression vectors. A variety of markers are known which are useful in selecting for transformed cell lines and generally comprise a gene whose expression confers a selectable phenotype on transformed cells when 30 the cells are grown in an appropriate selective medium. Such markers include, for example, genes which confer antibiotic resistance or sensitivity to the plasmid. Alternatively, several polyketides are naturally colored and this characteristic provides a built-in marker for 35

selecting cells successfully transformed by the present constructs.

5 The various PKS subunits of interest, or the cocktail of PKS genes, modules, active sites, or portions thereof, can be cloned into one or more recombinant vectors as individual cassettes, with separate control elements, or under the control of, e.g., a single promoter. The PKS subunits or cocktail components can include flanking restriction sites to allow for the easy  
10 deletion and insertion of other PKS subunits or cocktail components so that hybrid PKSs can be generated. The design of such unique restriction sites is known to those of skill in the art and can be accomplished using the techniques described above, such as site-directed  
15 mutagenesis and PCR.

Using these techniques, a novel plasmid, pRM5, (Figure 3 and Example 2) was constructed as a shuttle vector for the production of the polyketides described herein. Plasmid pRM5 includes the act genes encoding  
20 the KS/AT (ORF1), CLF (ORF2) and ACP (ORF3) PKS subunits, flanked by PacI, NsiI and XbaI restriction sites. Thus, analogous PKS subunits, encoded by other PKS genes, can be easily substituted for the existing act genes. (See, e.g., Example 4, describing the construction of hybrid  
25 vectors using pRM5 as the parent plasmid). The shuttle plasmid also contains the act KR gene (actIII), the cyclase gene (actVII), and a putative dehydratase gene (actIV), as well as a ColEI replicon (to allow transformation of *E. coli*), an appropriately truncated  
30 SCP2\* (low copy number) *Streptomyces* replicon, and the actII-ORF4 activator gene from the act cluster, which induces transcription from act promoters during the transition from growth phase to stationary phase in the vegetative mycelium. pRM5 carries the divergent  
35 actI/actIII promoter pair.

Methods for introducing the recombinant vectors of the present invention into suitable hosts are known to those of skill in the art and typically include the use of  $\text{CaCl}_2$  or other agents, such as divalent cations and DMSO. DNA can also be introduced into bacterial cells by electroporation. Once the PKSs are expressed, the polyketide producing colonies can be identified and isolated using known techniques. The produced polyketides can then be further characterized.

As explained above, the above-described recombinant methods also find utility in the catalytic biosynthesis of polyketides by large, modular PKSs. For example, 6-deoxyerythronolide B synthase (DEBS) catalyzes the biosynthesis of the erythromycin aglycone, 6-deoxyerythronolide B (17). Three open reading frames (*eryAI*, *eryAII*, and *eryAIII*) encode the DEBS polypeptides and span 32 kb in the *ery* gene cluster of the *Saccharopolyspora erythraea* genome. The genes are organized in six repeated units, each designated a "module." Each module encodes a set of active sites that, during polyketide biosynthesis, catalyzes the condensation of an additional monomer onto the growing chain. Each module includes an acyltransferase (AT),  $\beta$ -ketoacyl carrier protein synthase (KS), and acyl carrier protein (ACP) as well as a subset of reductive active sites ( $\beta$ -ketoreductase (KR), dehydratase (DH), enoyl reductase (ER)) (Figure 9). The number of reductive sites within a module corresponds to the extent of  $\beta$ -keto reduction in each condensation cycle. The thioesterase (TE) encoded at the end of module appears to catalyze lactone formation.

Due to the large sizes of *eryAI*, *eryAII*, and *eryAIII*, and the presence of multiple active sites, these genes can be conveniently cloned into a plasmid suitable for expression in a genetically engineered host cell,



such as CH999, using an *in vivo* recombination technique. This technique, described in Example 7 and summarized in Figure 10, utilizes derivatives of the plasmid pMAK705 (Hamilton et al. (1989) *J. Bacteriol.* 171:4617) to permit  
5 *in vivo* recombination between a temperature-sensitive donor plasmid, which is capable of replication at a first, permissive temperature and incapable of replication at a second, non-permissive temperature, and recipient plasmid. The *eryA* genes thus cloned gave pCK7,  
10 a derivative of pRM5 (McDaniel et al. (1993) *Science* 262:1546). A control plasmid, pCK7f, was constructed to carry a frameshift mutation in *eryAI*. pCK7 and pCK7f possess a *ColEI* replicon for genetic manipulation in *E. coli* as well as a truncated SCP2\* (low copy number)  
15 *Streptomyces* replicon. These plasmids also contain the divergent *actI/actIII* promoter pair and *actII-ORF4*, an activator gene, which is required for transcription from these promoters and activates expression during the transition from growth to stationary phase in the  
20 vegetative mycelium. High-level expression of PKS genes occurs at the onset of stationary phase of mycelial growth; the recombinant strains therefore produce "reporter" polyketides as secondary metabolites in a quasi-natural manner.

25 Recombinant vectors harboring modular PKSS can also be generated using techniques known in the art. For example, the PKS of interest can be obtained from an organism that expresses the same using recombinant techniques as describe above and exemplified in Examples  
30 7 and 8. For example, the gene can be isolated, subjected to mutation-producing protocols and reexpressed (see Example 8).

The method described above for producing polyketides synthesized by large, modular PKSS may be  
35 used to produce other polyketides as secondary

metabolites such as sugars,  $\beta$ -lactams, fatty acids, aminoglycosides, terpinoids, non-ribosomal peptides, prostanoid hormones and the like. In this manner, the polyketides can be produced after the host cell has


5 matured, thereby reducing any potential toxic or other bioactive effects of the polyketide on the host cell.

As with aromatic (Type II) and modular (Type I) PKSs, the above described methods also find utility in the catalytic biosynthesis of polyketides using the PKS

10 genes from fungi. Fungal PKSs, such as the 6-methylsalicylic acid PKS consist of a single multi-domain polypeptide which includes all active sites required for the biosynthesis of 6-methylsalicylic acid.

Using the above recombinant methods, a number



15 of polyketides have been produced. These compounds have the general structure (I)



wherein  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$  and  $i$  are as defined above. One group of such compounds are wherein:  $R^1$  is lower alkyl, preferably methyl;  $R^2$ ,  $R^3$  and  $R^6$  are hydrogen;  $R^6$  is  $-\text{CHR}^7-(\text{CO})-\text{R}^8$ ; and  $i$  is 0. A second


35 group of such compounds are wherein:  $R^1$  and  $R^6$  are lower

alkyl, preferably methyl;  $R^2$ ,  $R^3$  and  $R^5$  are hydrogen; and  $i$  is 0. Still a third group of such compounds are wherein:  $R^1$  and  $R^2$  are linked together to form a lower alkylene bridge  $-\text{CHR}^9-\text{CHR}^{10}$  wherein  $R^9$  and  $R^{10}$  are  
 5 independently selected from the group consisting of hydrogen, hydroxyl and lower alkyl, e.g.,  $-\text{CH}_2-\text{CHOH}-$ ;  $R^3$  and  $R^5$  are hydrogen;  $R^6$  is  $-\text{CHR}^7-(\text{CO})-\text{R}^8$  where  $R^8$  is hydrogen or lower alkyl, e.g.,  $-\text{CH}_2-(\text{CO})-\text{CH}_3$ ; and  $i$  is 0. Specific such compounds include the following compounds  
 10 9, 10 and 11 as follows:




35

11




Other novel polyketides within the scope of the invention are those having the structure


12




13




14



15




16



Preparation of compounds 9, 10, 11, 12, 13, 14, 15 and 16 is effected by cyclization of an enzyme-bound polyketide having the structure (II).


(II)




wherein  $R^{11}$ ,  $R^{12}$ ,  $R^{13}$  and  $R^{14}$  and E are as defined earlier herein. Examples of such compounds include: a first group wherein  $R^{11}$  is methyl and  $R^{12}$  is  $-\text{CH}_2(\text{CO})-\text{S}-\text{E}$ ; a second group wherein  $R^{11}$  is  $-\text{CH}_2(\text{CO})\text{CH}_3$  and  $R^{12}$  is  $-\text{S}-\text{E}$ ; a third group wherein  $R^{11}$  is  $-\text{CH}_2(\text{CO})\text{CH}_3$  and  $R^{12}$  is  $-\text{CH}_2(\text{CO})-\text{S}-\text{E}$ ; and a fourth group wherein  $R^{11}$  is  $-\text{CH}_2(\text{CO})\text{CH}_2(\text{CO})\text{CH}_3$  and  $R^{12}$  is  $-\text{CH}_2(\text{CO})-\text{S}-\text{E}$  (see Figure 8 for structural exemplification).

The remaining structures encompassed by generic formula (I)--i.e., structures other than 9, 10 and 11-- may be prepared from structures 9, 10 or 11 using routine synthetic organic methods well-known to those skilled in the art of organic chemistry, e.g., as described by H.O. House, Modern Synthetic Reactions, Second Edition (Menlo Park, CA: The Benjamin/Cummings Publishing Company, 1972), or by J. March, Advanced Organic Chemistry: Reactions, Mechanisms and Structure, 4th Ed. (New York: Wiley-Interscience, 1992), the disclosures of which are hereby incorporated by reference. Typically, as will be appreciated by those skilled in the art, incorporation of substituents on the aromatic rings will involve simple electrophilic aromatic addition reactions. Structures 12 and 13 may be modified in a similar manner to produce polyketides which are also intended to be within the scope of the present invention.


In addition, the above recombinant methods have been used to produce polyketide compound having the general structure (III)



general structure (IV)



15 and general structure (V)



Particularly preferred compounds of structural formulas (III), (IV) and (V) are wherein:  $R^2$  is hydrogen and  $i$  is 0.

30 As disclosed hereinabove and in the Examples which follow, a system has been developed to functionally express recombinant PKSS and to produce novel aromatic polyketides (Examples 1-6). This technology has been extrapolated to larger gene clusters using an *in vivo* recombination strategy (Kao et al. *Science* (1994)

35



265:509-512; see Examples 7 and 8). These systems may be used to genetically manipulate polyketide biosynthesis to generate libraries of synthetic products.

5 A typical pathway for polyketide biosynthesis is shown in Figure 10. Generally, polyketide synthesis occurs in three stages. In the first stage, catalyzed by the PKS, a nascent polyketide backbone is generated from monomeric CoA thioesters. In the second stage this backbone is regiospecifically cyclized. While some  
10 cyclization reactions are controlled by the PKS itself, others result from activities of downstream enzymes. In the final stage, the cyclized intermediate is modified further by the action of mechanistically diverse "tailoring enzymes," giving rise to the natural product.

15 More particularly, polyketide biosynthesis begins with a primer unit loading on to the active site of the condensing enzyme,  $\beta$ -keto acyl synthase (KS). An extender unit (usually malonate) is then transferred to the pathetheinyl arm of the acyl carrier protein (ACP).  
20 The KS catalyzes the condensation between the ACP-bound malonate and the starter unit. Additional extender units are added sequentially until the nascent polyketide chain has grown to a desired chain length determined by the protein chain length factor (CLF), perhaps together with  
25 the KS. Thus, the KS, CLF and the ACP form a minimal set to generate a polyketide backbone, and are together called the "minimal PKS." The nascent polyketide chain is then subjected to regiospecific ketoreduction by a ketoreductase (KR) if it exists. Cyclases (CYC) and  
30 aromatases (ARO) later catalyze regiospecific ring formation events through intramolecular aldol condensations. The cyclized intermediate may then undergo additional regiospecific and/or stereospecific modifications (e.g., O-methylation, hydroxylation,

35

glycosylation, etc.) controlled by downstream tailoring enzymes).

Acetyl CoA is the usual starter unit for most aromatic polyketides. However, malonyl CoA (Gatenbeck, S. *Biochem. Biophys. Res. Commun.* (1961) 6:422-426) and propionyl CoA (Paulick, R. C. et al. *J. Am. Chem. Soc.* (1976) 98:3370-3371) are primers for many members of the tetracycline and anthracycline classes of polyketides, respectively (Figure 11). Daunorubicin PKS can also accept acetate, butyrate, and isobutyrate as starter units. (Oki, T. et al. *J. Antibiot.* (1981) 34:783-790; Yoshimoto, A. et al. *J. Antibiot.* (1993) 46:1758-1761).

The act KR can productively interact with all minimal PKSs studied thus far and is both necessary and sufficient to catalyze a C-9 ketoreduction. Although homologous KRs have been found in other PKS clusters, they catalyze ketoreduction with the same regiospecificity. However, the structures of frenolicin, griseusin and daunorubicin (Figure 11) suggest that an additional C-17 ketoreduction occurs in these biosynthetic pathways. Likewise, several angucyclines undergo a C-15 ketoreduction, which occurs before the nascent polyketide chain is cyclized (Gould, S. J. et al. *J. Am. Chem. Soc.* (1992) 114:10066-10068). The ketoreductases responsible for C-15 and C-17 reductions have not yet been identified; however, two homologous KRs have been found in the daunorubicin PKS cluster (Grimm, A. et al. *Gene* (1994) 151:1-10; Ye, J. et al. *J. Bacteriol.* (1994) 176:6270-6280). It is likely that they catalyze the C-9 and C-17 reductions. Thus, KRs responsible for regiospecific reduction of the carbon chain backbone at positions other than C-9 may also be targets for use in the construction of combinatorial libraries.

The formation of the first two six-membered rings in the biosynthesis of most naturally occurring bacterial aromatic polyketides is controlled by PKS subunits; further ring closures are controlled by additional cyclases and modifying enzymes. The structural diversity introduced via these reactions appears to be greater than via the first two cyclizations. However, certain preferred patterns are observed, which suggests that at least some of these downstream cyclases may be useful for the construction of combinatorial libraries. For example, the pyran ring in isochromanequinones (Figure 11) is invariably formed via cyclization between C-3 and C-15; two stereochemically distinct classes of products are observed (see, for example, the structures of actinorhodin and frenolicin in (Figure 11)). In anthracyclines and tetracyclines a third aldol condensation usually occurs between C-3 and C-16, whereas in unreduced tetracenomycins (Figure 11) and related compounds it occurs between C-5 and C-18, and in angucyclines (Figure 11) it occurs between C-4 and C-17. Representative gene(s) encoding a few of these enzymes have already been cloned (Fernández-Moreno, M. A., et al. *J. Biol. Chem.* (1994) 269:24854-24863; Shen, B. et al. *Biochemistry* (1993) 32:11149-11154). At least some cyclases might recognize chains of altered lengths and/or degrees of reduction, thereby increasing the diversity of aromatic polyketide combinatorial libraries.

In the absence of downstream cyclases, polyketide chains undergo non-enzymatic reactions. Recently, some degree of predictability has emerged within this repertoire of possibilities. For instance, hemiketals and benzene rings are two common moieties seen on the methyl end. Hemiketals are formed with an appropriately-positioned enol and can be followed by a dehydration. Benzene rings are formed with longer

uncyclized methyl terminus. On the carboxyl terminus, a  $\gamma$ -pyrone ring formed by three ketide units is frequently observed. Spontaneous decarboxylations occur on free carboxyl ends activated by the existence of a  $\beta$ -carbonyl.

5           A cyclized intermediate can undergo various types of modifications to generate the final natural product. The recurrence of certain structural motifs among naturally occurring aromatic polyketides suggests that some tailoring enzymes, particularly group  
10           transferases, may be combinatorially useful. Two examples are discussed below.

          O-methylation is a common downstream modification. Although several SAM-dependent  
15           O-methyltransferase genes have been found in PKS gene clusters (Decker, H. et al. *J. Bacteriol.* (1993) 175:3876-3886), their specificities have not been systematically studied as yet. Perhaps some of them could be useful for combinatorial biosynthesis. For instance, O-11-methylation occurs in several members of  
20           the anthracycline, tetracenomycin, and angucycline classes of aromatic polyketides (Figure 11).

          Both aromatic and complex polyketides are often glycosylated. In many cases (e.g. doxorubicin and erythromycin) absence of the sugar group(s) results in  
25           considerably weaker bioactivity. There is tremendous diversity in both the types and numbers of sugar units attached to naturally occurring polyketide aglycones. In particular, deoxy- and aminosugars are commonly found. Regiochemical preferences can be detected in many  
30           glycosylated natural products. Among anthracyclines, O-17 is frequently glycosylated, whereas among angucyclines, C-10 is usually glycosylated. Glycosyltransferases involved in erythromycin biosynthesis may have relaxed specificities for the  
35           aglycone moiety (Donadio, S. et al. *Science* (1991)

252:675-679). An elloramycin glycosyltransferase may be able to recognize an unnatural NDP-sugar unit and attach it regiospecifically to an aromatic polyketide aglycone (Decker, H. et al. *Angew. Chem.* (1995), in press). These  
5 early results suggest that glycosyltransferases derived from secondary metabolic pathways have unique properties and may be attractive targets for use in the generation of combinatorial libraries.

Although modular PKs have not been extensively  
10 analyzed, the one-to-one correspondence between active sites and product structure (Figure 9), together with the incredible chemical diversity observed among naturally occurring "complex" polyketides, indicates that the combinatorial potential within these multienzyme systems  
15 could be considerably greater than that for aromatic PKs. For example, a wider range of primer units including aliphatic monomers (acetate, propionate, butyrate, isovalerate, etc.), aromatics (aminohydroxybenzoic acid), alicyclics (cyclohexanoic  
20 acid), and heterocyclics (pipecolic acid) are found in various macrocyclic polyketides. Recent studies have shown that modular PKs have relaxed specificity for their starter units (Kao et al. *Science* (1994), *supra*). The degree of  $\beta$ -ketoreduction following a condensation  
25 reaction can also be altered by genetic manipulation (Donadio et al. *Science* (1991), *supra*; Donadio, S. et al. *Proc. Natl. Acad. Sci. USA* (1993) 90:7119-7123). Likewise, the size of the polyketide product can be varied by designing mutants with the appropriate number  
30 of modules (Kao, C. M. et al. *J. Am. Chem. Soc.* (1994) 116:11612-11613). Modular PKs also exhibit considerable variety with regards to the choice of extender units in each condensation cycle, although it remains to be seen to what extent this property can be manipulated. Lastly,  
35 these enzymes are particularly well-known for generating

an impressive range of asymmetric centers in their products in a highly controlled manner. Thus, the combinatorial potential within modular PKS pathways could be virtually unlimited.

5           Like the actinomycetes, filamentous fungi are a rich source of polyketide natural products. The fact that fungal PKSs, such as the 6-methylsalicylic acid synthase (6-MSAS) and the mevinolin synthase, are encoded by single multi-domain proteins (Beck et al. *Eur. J. Biochem.* (1990), *supra*; Davis, R. et al. *Abstr. Genet. Ind. Microorg. Meeting, supra*) indicates that they may also be targeted for combinatorial mutagenesis. Moreover, fungal PKSs can be functionally expressed in *S. coelicolor* CH999 using the genetic strategy outlined  
10 above. Chain lengths not observed in bacterial aromatic polyketides (e.g. tetraketides, pentaketides and hexaketides) have been found among fungal aromatic polyketides (O'Hagan, D. *The Polyketide Metabolites* (Ellis Horwood, Chichester, U.K., 1991). Likewise, the  
15 cyclization patterns of fungal aromatic polyketides are quite different from those observed in bacterial aromatic polyketides (*Id.*). In contrast with modular PKSs from bacteria, branched methyl groups are introduced into fungal polyketide backbones by S-adenosylmethionine-  
20 dependent methyltransferases; in the case of the mevinolin PKS (Davis, R. et al. *Abstr. Genet. Ind. Microorg. Meeting, supra*), this activity is encoded as one domain within a monocistronic PKS. It is now possible to experimentally evaluate whether these and  
25 other sources of chemical diversity in fungal polyketides are indeed amenable to combinatorial manipulation.

30           Based on the above-discussed state of the art, and the results presented in Examples 1-8 hereinbelow, the inventors herein have developed the following set of  
35 design rules for rationally or stochastically

manipulating early biosynthetic steps in aromatic polyketide pathways including chain synthesis, C-9 ketoreduction, and the formation of the first two aromatic rings. If each biosynthetic degree of freedom was independent of all others, then it should be possible to design a single combinatorial library of  $N_1 \times N_2 \times \dots N_1 \times \dots N_{n-1} \times N_n$  clones, where  $N_i$  is the number of ways in which the  $i$ th degree of freedom can be exploited. In practice however, not all enzymatic degrees of freedom are independent. Therefore, to minimize redundancy, it is preferable to design several sub-libraries of aromatic polyketide-producing clones.

(1) Chain length. Polyketide carbon chain length is dictated by the minimal PKS (Figure 12). Within the minimal PKS, the acyl carrier protein can be interchanged without affecting specificity, whereas the chain length factor is crucial. Although some ketosynthase/chain length factor combinations are functional, others are not; therefore, biosynthesis of a polyketide chain of specified length can be insured with a minimal PKS in which both the ketosynthase and chain length factor originate from the same PKS gene cluster. So far, chain lengths of 16 (octaketide), 18 (nonaketide), 20 (decaaketide), and 24 carbons (dodecaaketide) can be generated with minimal PKSs from the *act*, *fren*, *tcm*, and, *whiE* PKS clusters, respectively (McDaniel et al. *Science* (1993), *supra*; McDaniel et al. *J. Am. Chem. Soc.* (1993), *supra*; McDaniel et al. *Proc. Natl. Acad. Sci. USA* (1994), *supra*). The *whiE* minimal PKS can also generate 22-carbon backbones in the presence of a KR, suggesting a degree of relaxed chain length control as found for the *fren* PKS.

(2) Ketoreduction. Ketoreduction requires a ketoreductase (Figure 12). The *act* KR can catalyze reduction of the C-9 carbonyl (counting from the carboxyl

end) of a nascent polyketide backbone of any length studied so far. Furthermore, the act KR is compatible with all the minimal PKSs mentioned above. Homologous ketoreductases have been identified in other PKS clusters  
5 (Sherman, D.H., et al. *EMBO J.* (1989) 8:2717-2725; Yu, T.-W. et al. *J. Bacteriol.* (1994) 176:2627-2534; Bibb, M.J. et al. *Gene* (1994) 142:31-39). These enzymes may catalyze ketoreduction at C-9 as well since all the corresponding natural products undergo this modification.  
10 In unusual circumstances, C-7 ketoreductions have also been observed with the act KR.

(3) Cyclization of the first ring. Although the minimal PKS alone can control formation of the first ring, the regiospecific course of this reaction may be  
15 influenced by other PKS proteins. For example, most minimal PKSs studied so far produce polyketides with C-7/C-12 cyclizations when present alone (Figure 12). In contrast, the tcm minimal PKS alone generates both C-7/C-12 and C-9/C-14 cyclized products. The presence of  
20 a ketoreductase with any minimal PKS restricts the nascent polyketide chain to cyclize exclusively with respect to the position of ketoreduction: C-7/C-12 cyclization for C-9 ketoreduction and C-5/C-10 cyclization for C-7 ketoreduction (McDaniel, R. et al. *J.*  
25 *Am. Chem. Soc.* (1993) 115:11671-11675; McDaniel, R. et al. *Proc. Natl. Acad. Sci. USA* (1994) 91:11542-11546; McDaniel, R. et al. *J. Am. Chem. Soc.* (1994) 116:10855-10859). Likewise, use of the TcmN enzyme alters the regiospecificity to C-9/C-14 cyclizations for unreduced  
30 polyketides of different lengths, but has no effect on reduced molecules (see Example 5 below).

(4) First ring aromatization. The first ring in unreduced polyketides aromatizes non-catalytically. In contrast, an aromatizing subunit is required for  
35 reduced polyketides (Figure 12). There appears to be a



hierarchy in the chain length specificity of these subunits from different PKS clusters. For example, the act ARO will recognize only 16-carbon chains (McDaniel et al. *Proc. Natl. Acad. Sci. USA* (1994), *supra*), the fren ARO recognizes both 16- and 18-carbon chains, while the gris ARO recognizes chains of 16, 18, and 20 carbons.

(5) Second ring cyclization. C-5/C-14 cyclization of the second ring of reduced polyketides may be achieved with an appropriate cyclase (Figure 12). While the act CYC can cyclize octa- and nonaketides, it does not recognize longer chains. No equivalent C-5/C-14 cyclase with specificity for decaketides or longer chains has been identified, although the structures of natural products such as griseusin imply their existence. In the case of sufficiently long unreduced chains with a C-9/C-14 first ring, formation of a C-7/C-16 second ring is catalyzed by the minimal PKS (Figure 12) (McDaniel et al. *Proc. Natl. Acad. Sci. USA* (1994), *supra*).

(6) Additional cyclizations. The KS, CLF, ACP, KR, ARO, and CYC subunits of the PKS together catalyze the formation of an intermediate with a defined chain length, reduction pattern, and first two cyclizations. While the biosynthesis of naturally occurring polyketides typically requires the activity of downstream cyclases and other modifying enzymes to generate the characteristic biologically active product, subsequent reactions in the biosynthesis of engineered polyketides described here and in our earlier work occur in the absence of specific enzymes and are determined by the different physical and chemical properties of the individual molecules. Presumably reflecting such chemical possibilities and constraints, consistent patterns have been observed, leading to some degree of predictability. Two common moieties formed by the uncyclized methyl terminus of polyketide chains are

hemiketals and benzene rings. Formation of a hemiketal occurs in the presence of an appropriately positioned enol and can be followed by a dehydration since both the hydrated and dehydrated forms are often isolated (Figure 13 (a)) (McDaniel, R. et al. *Science* (1993) 262:15461550; McDaniel, R. et al. *J. Am. Chem. Soc.* (1994) 116:10855-10859; Fu, H. et al. *J. Am. Chem. Soc.* (1994) 116:4166-4170), while benzene ring formation occurs with longer unprocessed methyl ends (Figure 13 (b)) (Fu et al. *J. Am. Chem. Soc.* (1994), *supra*). The most frequently observed moiety at the carboxyl terminus of the chain is a  $\gamma$ -pyrone ring formed by three ketide units (Figure 13 (c)) (McDaniel et al. *J. Am. Chem. Soc.* (1994), *supra*; Fu et al. *J. Am. Chem. Soc.* (1994), *supra*; Fu, H., et al. *Biochemistry* (1994) 33:9321-9326; Fu, H. et al. *Chem. & Biol.* (1994) 1:205-210; Zhang, H.-l. et al. *J. Org. Chem.* (1990) 55:1682-1684); if a free carboxylic acid remains, decarboxylation typically occurs if a  $\beta$ -carbonyl exists (Figure 13 (d)) (McDaniel et al. *Science* (1993), *supra*; McDaniel, R., Ebert-Khosla, S., Hopwood, D.A. & Khosla, C. *J. Am. Chem. Soc.* (1993), *supra*; Kao, C.M. et al. *J. Am. Chem. Soc.* (1994) 116:11612-11613). Many aldol condensations can be predicted as well, bearing in mind that the methyl and carboxyl ends tend preferentially to cyclize independently but will co-cyclize if no alternative exists (Figure 13 (e)) (McDaniel et al. *Proc. Natl. Acad. Sci. USA* (1994), *supra*). These non-enzymatic cyclization patterns observed *in vivo* are also consistent with earlier biomimetic studies (Griffin, D.A. et al. *J. Chem. Soc. Perkin Trans.* (1984) 1:1035-1042).

Taken together with the structures of other naturally occurring bacterial aromatic polyketides, the design rules presented above can be extrapolated to estimate the extent of molecular diversity that might be generated via *in vivo* combinatorial biosynthesis of, for

example, reduced and unreduced polyketides. For reduced polyketides, the identified degrees of freedom include chain length, aromatization of the first ring, and cyclization of the second ring. For unreduced ones, these include chain length and regiospecificity of the first ring cyclization. The number of accessible structures is the product of the number of ways in which each degree of freedom can be varied. Chains of five different lengths have so far been manipulated (16-, 18- 20-, 22- and 24-carbon lengths). From the structure and deduced biosynthetic pathways of the dynemicin anthraquinone (Tokiwa, Y. et al. *J. Am. Chem. Soc.* (1992) 114:4107-4110), simaomicin (Carter, G.T. et al. *J. Org. Chem.* (1989) 54:4321-4323), and benastatin (Aoyama, T. et al. *J. Antibiot.* (1992) 45:1767-1772), the isolation of minimal PKSs that generate 14-, 26-, and possibly 28-carbon backbones, respectively, is anticipated, bringing the potential number to eight. Cloning of such minimal PKSs can be accomplished using the genes for minimal PKSs which have previously been isolated, such as the actI genes (Sherman et al. *EMBO J.* (1989), *supra*; Yu et al. *J. Bacteriol.* (1994), *supra*; Bibb et al. *Gene* (1994), *supra*; Malpartida, F. et al. *Nature* (1987) 325:818-821). Reduced chains can either be aromatized or not; a second ring cyclase is optional where the first ring is aromatized (Figure 12). The regiospecificity of the first cyclization of an unreduced chain can be varied, depending on the presence of an enzyme like TcmN.

For example, for reduced polyketides the relevant degrees of freedom include the chain length (which can be manipulated in at least seven ways), the first ring aromatization (which can be manipulated in at least two ways), and the second ring cyclization (which can be manipulated in at least two ways for aromatized intermediates only). For unreduced polyketides, the

regiospecificity of the first cyclization can also be manipulated. Thus, the combinatorial potential for reduced polyketides is at least  $7 \times 3 = 21$ ; for unreduced polyketides the combinatorial potential is at least  $7 \times 2 = 14$ . Moreover, these numbers do not include additional minor products, on the order of 5 to 10 per major product, that are produced in the recombinant strains through non-enzymatic or non-specific enzyme catalyzed steps. Thus, the number of polyketides that can be generated from combinatorial manipulation of only the first few steps in aromatic polyketide biosynthesis is on the order of a few hundred. Thus, genetically engineered biosynthesis represents a potentially unlimited source of chemical diversity for drug discovery.

The number of potential novel polyketides increase geometrically as new degrees of freedom are exploited and/or protein engineering strategies are brought to bear on the task of creating enzyme subunits with specificities not observed in nature. For example, non-acetate starter units can be incorporated into polyketide backbones (e.g. propionate in daunorubicin and malonamide in oxytetracycline). Furthermore, enzymes that catalyze downstream cyclizations and late-step modifications, such as group transfer reactions and oxidoreductions commonly seen in naturally occurring polyketides, can be studied along the lines presented here and elsewhere. It is therefore possible that at least some of these degrees of freedom can be combinatorially exploited to generate libraries of synthetic products with structural diversity that is comparable to that observed in nature.

### C. Experimental

Below are examples of specific embodiments for carrying out the present invention. The examples are offered for illustrative purposes only, and are not intended to limit the scope of the present invention in any way.

Efforts have been made to ensure accuracy with respect to numbers used (e.g., amounts, temperatures, etc.), but some experimental error and deviation should, of course, be allowed for.

### Materials and Methods

Bacterial strains, plasmids, and culture conditions. *S. coelicolor* CH999 was used as a host for transformation by all plasmids. The construction of this strain is described below. DNA manipulations were performed in *Escherichia coli* MC1061. Plasmids were passaged through *E. coli* ET12567 (*dam dcm hsdS*  $\text{Cm}^r$ ) (MacNeil, D.J. *J. Bacteriol.* (1988) 170:5607) to generate unmethylated DNA prior to transformation of *S. coelicolor*. *E. coli* strains were grown under standard conditions. *S. coelicolor* strains were grown on R2YE agar plates (Hopwood, D.A. et al. *Genetic manipulation of Streptomyces. A laboratory manual*. The John Innes Foundation: Norwich, 1985).

Manipulation of DNA and organisms. Polymerase chain reaction (PCR) was performed using Taq polymerase (Perkin Elmer Cetus) under conditions recommended by the enzyme manufacturer. Standard in vitro techniques were used for DNA manipulations (Sambrook, et al. *Molecular Cloning: A Laboratory Manual* (Current Edition)). *E. coli* was transformed with a Bio-Rad *E. Coli* Pulsing apparatus using protocols provided by Bio-Rad. *S. coelicolor* was transformed by standard procedures

(Hopwood, D.A. et al. *Genetic manipulation of Streptomyces. A laboratory manual*. The John Innes Foundation: Norwich, 1985) and transformants were selected using 2 ml of a 500 mg/ml thiostrepton overlay.

5

**Construction of plasmids containing recombinant PKSs.** All plasmids are derivatives of pRM5, described below. *fren* PKS genes were amplified via PCR with 5' and 3' restriction sites flanking the genes in accordance with the location of cloning sites on pRM5 (i.e. *PacI*-*NsiI* for ORF1, *NsiI*-*XbaI* for ORF2, and *XbaI*-*PstI* for ORF3). Following subcloning and sequencing, the amplified fragments were cloned in place of the corresponding fragments in pRM5 to generate the plasmids for transformation.

10  
15

**Production and purification of polyketides.**

For initial screening, all strains were grown at 30°C as confluent lawns on 10-30 plates each containing approximately 30 ml of agar medium for 6-8 days. Additional plates were made as needed to obtain sufficient material for complete characterization. CH999 was a negative control when screening for potential polyketides. The agar was finely chopped and extracted with ethyl acetate/1% acetic acid or ethyl acetate:methanol (4:1)/1% acetic acid. The concentrated extract was then flashed through a silica gel (Baker 40 mm) chromatography column in ethyl acetate/1% acetic acid. Alternatively, the extract was applied to a Florisil column (Fisher Scientific) and eluted with ethyl acetate:ethanol:acetic acid (17:2:1). The primary yellow fraction was further purified via high-performance liquid chromatography (HPLC) using a 20-60% acetonitrile/water/1% acetic acid gradient on a preparative reverse phase (C-18) column (Beckman).

20  
25  
30  
35

Absorbance was monitored at 280nm and 410nm. In general, the yield of purified product from these strains was approximately 10 mg/l for compounds 1 and 2 (Figure 4), and 5 mg/l for compounds 7 and 8 (Figure 7).

5                   SEK4, (12), was produced and purified as follows. CH999/pSEK4 was grown on 90 agar plates (~ 34 ml/plate) at 30°C for 7 days. The agar was chopped and extracted with ethyl acetate/methanol (4/1) in the presence of 1% acetic acid (3 x 1000 ml). Following  
10 removal of the solvent under vacuum, 200 ml of ethyl acetate containing 1% acetic acid were added. The precipitate was filtered and discarded, and the solvent was evaporated to dryness. The product mixture was applied to a Florisil column (Fisher Scientific), and  
15 eluted with ethyl acetate containing 3% acetic acid. The first 100 ml fraction was collected, and concentrated down to 5 ml. 1 ml methanol was added, and the mixture was kept at 4°C overnight. The precipitate was collected by filtration, and washed with ethyl acetate to give 850  
20 mg of pure product.  $R_f = 0.48$  (ethyl acetate with 1% acetic acid). Results from NMR spectroscopy on SEK4 are reported in Table 4. FAB HRMS (NBA),  $M + H^+$ , calculated m/e 319.0818, observed m/e 319.0820.

To produce SEK15 (13) and SEK15b (16),  
25 CH999/pSEK15 was grown on 90 agar plates, and the product was extracted in the same manner as SEK4. The mixture was applied to a Florisil column (ethyl acetate with 5% acetic acid), and fractions containing the major products were combined and evaporated to dryness. The products  
30 were further purified using preparative C-18 reverse phase HPLC (Beckman) (mobile phase: acetonitrile/water = 1/10 to 3/5 gradient in the presence of 1% acetic acid). The yield of SEK15, (13), was 250 mg.  $R_f = 0.41$  (ethyl acetate with 1% acetic acid). Results from NMR  
35 spectroscopy on SEK4 are reported in Table 4. FAB HRMS

(NBA),  $M + H^+$ , calculated  $m/e$  385.0923, observed  $m/e$  385.0920.

[1,2- $^{13}C_2$ ] acetate feeding experiments. Two 2  
5 1 flasks each containing 400 ml of modified NMP medium  
(Strauch, E. et al. *Mol. Microbiol.* (1991) 5:289) were  
inoculated with spores of *S. coelicolor* CH999/pRM18,  
CH999/pSEK4 or CH999/pSEK15, and incubated in a shaker at  
30 degrees C and 300 rpm. To each flask, 50 mg of sodium  
10 [1,2- $^{13}C_2$ ] acetate (Aldrich) was added at 72 and 96 hrs.  
After 120 hrs, the cultures were pooled and extracted  
with two 500 ml volumes of ethyl acetate/1% acetic acid.  
The organic phase was kept and purification proceeded as  
described above.  $^{13}C$  NMR data indicate approximately a  
15 2-3% enrichment for the CH999/pRM18 product; a 0.5-1%  
enrichment for SEK4 and a 1-2% enrichment for SEK15.

NMR Spectroscopy. All spectra were recorded on  
a Varian XL-400 except for HETCOR analysis of RM18 (10)  
20 (Figure 8), which was performed on a Nicolet NT-360.  $^{13}C$   
spectra were acquired with continuous broadband proton  
decoupling. For NOE studies of RM18 (10), the  
one-dimensional difference method was employed. All  
compounds were dissolved in DMSO- $d_6$  (Sigma, 99+ atom % D)  
25 and spectra were referenced internally to the solvent.  
Hydroxyl resonances were identified by adding  $D_2O$   
(Aldrich, 99 atom % D) and checking for disappearance of  
signal.

30

#### Example 1

##### Production of *S. coelicolor* CH999

An *S. coelicolor* host cell, genetically  
engineered to remove the native act gene cluster, and  
termed CH999, was constructed using *S. coelicolor* CH1  
35 (Khosla, C. *Molec. Microbiol.* (1992) 6:3237), using the



strategy depicted in Figure 2. (CH1 is derived from *S. coelicolor* B385 (Rudd, B.A.M. Genetics of Pigmented Secondary Metabolites in *Streptomyces coelicolor* (1978) Ph.D. Thesis, University of East Anglia, Norwich, England.) CH1 includes the act gene cluster which codes for enzymes involved in the biosynthesis and export of the polyketide antibiotic actinorhodin. The cluster is made up of the PKS genes, flanked by several post-PKS biosynthetic genes including those involved in cyclization, aromatization, and subsequent chemical tailoring (Figure 2A). Also present are the genes responsible for transcriptional activation of the act genes. The act gene cluster was deleted from CH1 using homologous recombination as described in Khosla, C. et al. *Molec. Microbiol.* (1992) 6:3237.

In particular, plasmid pLRermEts (Figure 2B) was constructed with the following features: a *ColEI* replicon from pBR322, the temperature sensitive replicon from pSG5 (Muth, G. et al. *Mol. Gen. Genet.* (1989) 219:341), ampicillin and thiostrepton resistance markers, and a disruption cassette including a 2 kb *BamHI/XhoI* fragment from the 5' end of the act cluster, a 1.5 kb *ermE* fragment (Khosla, C. et al. *Molec. Microbiol.* (1992) 6:3237), and a 1.9 kb *SphI/PstI* fragment from the 3' end of the act cluster. The 5' fragment extended from the *BamHI* site 1 (Malpartida, F. and Hopwood, D.A. *Nature* (1984) 309:462; Malpartida, F. and Hopwood, D.A. *Mol. Gen. Genet.* (1986) 205:66) downstream to a *XhoI* site. The 3' fragment extended from *PstI* site 20 upstream to *SphI* site 19.2 (Fernandez-Moreno, M.A. et al. *J. Biol. Chem.* (1992) 267:19278). The 5' and 3' fragments (shown as hatched DNA in Figure 2) were cloned in the same relative orientation as in the act cluster. CH1 was transformed with pLRermEts. The plasmid was subsequently cured from candidate transformants by streaking

non-selectively at 39°C. Several colonies that were lincomycin resistant, thiostrepton sensitive, and unable to produce actinorhodin, were isolated and checked via Southern blotting. One of them was designated CH999.

5

### Example 2

#### Production of the Recombinant Vector pRM5

Shuttle plasmids are used to express recombinant PKSs in CH999. Such plasmids typically include a *colEI* replicon, an appropriately truncated SCP2\* *Streptomyces* replicon, two act-promoters to allow for bidirectional cloning, the gene encoding the actII-ORF4 activator which induces transcription from act promoters during the transition from growth phase to stationary phase, and appropriate marker genes. Restriction sites have been engineered into these vectors to facilitate the combinatorial construction of PKS gene clusters starting from cassettes encoding individual subunits (or domains) of naturally occurring PKSs. The primary advantages of this method are that (i) all relevant biosynthetic genes are plasmid-borne and therefore amenable to facile manipulation and mutagenesis in *E.coli*, (ii) the entire library of PKS gene clusters can be expressed in the same bacterial host which is genetically and physiologically well-characterized and presumably contains most, if not all, ancillary activities required for *in vivo* production of polyketides, (iii) polyketides are produced in a secondary metabolite-like manner, thereby alleviating the toxic effects of synthesizing potentially bioactive compounds *in vivo*, and (iv) molecules thus produced undergo fewer side reactions than if the same pathways were expressed in wild-type organisms or blocked mutants.

pRM5 (Figure 3) was the shuttle plasmid used for expressing PKSs in CH999. It includes a *ColEI*

replicon to allow genetic engineering in *E. coli*, an appropriately truncated SCP2\* (low copy number) *Streptomyces* replicon, and the actII-ORF4 activator gene from the act cluster, which induces transcription from act promoters during the transition from growth phase to stationary phase in the vegetative mycelium. As shown in Figure 3, pRM5 carries the divergent actI/actIII promoter pair, together with convenient cloning sites to facilitate the insertion of a variety of engineered PKS genes downstream of both promoters. pRM5 lacks the par locus of SCP2\*; as a result the plasmid is slightly unstable (approx. 2% loss in the absence of thiostrepton). This feature was deliberately introduced in order to allow for rapid confirmation that a phenotype of interest could be unambiguously assigned to the plasmid-borne mutant PKS. The recombinant PKSs from pRM5 are expressed approximately at the transition from exponential to stationary phase of growth, in good yields.

pRM5 was constructed as follows. A 10.5 kb *SphI/HindIII* fragment from pIJ903 (containing a portion of the fertility locus and the origin of replication of SCP2\* as well as the *colEI* origin of replication and the  $\beta$ -lactamase gene from pBR327) (Lydiate, D.J. Gene (1985) 35:223) was ligated with a 1.5 kb *HindIII/SphI* *tsr* gene cassette to yield pRM1. pRM5 was constructed by inserting the following two fragments between the unique *HindIII* and *EcoRI* sites of pRM1: a 0.3 kb *HindIII/HpaI*(blunt) fragment carrying a transcription terminator from phage fd (Khosla, C. et al. Molec. Microbiol. (1992) 6:3237), and a 10 kb fragment from the act cluster extending from the *NcoI* site (1 kb upstream of the actII-ORF4 activator gene) (Hallam, S.E. et al. Gene (1988) 74:305; Fernandez-Moreno, M.A. et al. Cell (1991) 66:769; Caballero, J.L. Mol. Gen. Genet. (1991)

230:401) to the *Pst*I site downstream of the *act*I-VII-IV genes (Fernandez-Moreno, M.A. et al. *J. Biol. Chem.* (1992) 267:19278).

5 To facilitate the expression of any desired recombinant PKS under the control of the *act*I promoter (which is activated by the *act*II-ORF4 gene product), restriction sites for *Pac*I, *Nsi*I, *Xba*I, and *Pst*I were engineered into the *act* DNA in intercistronic positions. In *prM5*, as well as in all other PKS expression plasmids  
10 described here, ORF1, 2, and 3 alleles were cloned between these sites as cassettes engineered with their own RBSSs.

In particular, in most naturally occurring aromatic polyketide synthase gene clusters in  
15 actinomycetes, ORF1 and ORF2 are translationally coupled. In order to facilitate construction of recombinant PKSS, the ORF1 and ORF2 alleles used here were cloned as independent (uncoupled) cassettes. For *act* ORF1, the following sequence was engineered into *prM5*:  
20 **CCACCGGACGAACGCATCGATTAATTAAGGAGGACCATCATG**, where the boldfaced sequence corresponds to upstream DNA from the *act*I region, TTAATTAA is the *Pac*I recognition site, and **ATG** is the start codon of *act* ORF1. The following sequence was engineered between *act* ORF1 and ORF2:  
25 **NTGAATGCATGGAGGAGCCATCATG**, where **TGA** and **ATG** are the stop and start codons of ORF1 and ORF2, respectively, ATGCAT is the *Nsi*I recognition site, and the replacement of N (A in *act* DNA, A or G in alleles from other PKSS) with a C results in translational decoupling. The following  
30 sequence was engineered downstream of *act* ORF2: **TAATCTAGA**, where **TAA** is the stop codon, and TCTAGA is the *Xba*I recognition site. This allowed fusion of *act* ORF1 and ORF2 (engineered as above) to an *Xba*I site that had been engineered upstream of *act* ORF3 (Khosla, C. et al.  
35 *Molec. Microbiol.* (1992) 6:3237). As a control, *prM2* was

constructed, identical to pRM5, but lacking any of the engineered sequences. ORF1 and ORF2 in pRM2 are translationally coupled. Comparison of the product profiles of CH999/pRM2 and CH999/pRM5 revealed that the  
5 decoupling strategy described here had no detectable influence on product distribution or product levels.

### Example 3

#### Polyketides Produced using CH999 Transformed with pRM5

10 Plasmid pRM5 was introduced into *S. coelicolor* CH999 using standard techniques. (See, e.g., Sambrook, et al. *Molecular Cloning: A Laboratory Manual* (Current Edition.) CH999 transformed with pRM5 produced a large amount of yellowish-brown material. The two most  
15 abundant products were characterized by NMR and mass spectroscopy as aloesaponarin II (2) (Bartel, P.L. et al. *J. Bacteriol.* (1990) 172:4816) and its carboxylated analog, 3,8-dihydroxy-1-methylanthraquinone-2-carboxylic acid (1) (Cameron, D.W. et al. *Liebigs Ann. Chem.* (1989) 7:699) (Figure 4). It is presumed that 2 is derived from  
20 1 by non-enzymatic decarboxylation (Bartel, P.L. et al. *J. Bacteriol.* (1990) 172:4816). Compounds 1 and 2 were present in approximately a 1:5 molar ratio. Approximately 100 mg of the mixture could be easily  
25 purified from 1 l of culture. The CH999/pRM5 host-vector system was therefore functioning as expected to produce significant amounts of a stable, only minimally modified polyketide metabolite. The production of 1 and 2 is consistent with the proposed pathway of actinorhodin  
30 biosynthesis (Bartel, P.L. et al. *J. Bacteriol.* (1990) 172:4816). Both metabolites, like the actinorhodin backbone, are derived from a 16-carbon polyketide with a single ketoreduction at C-9.

When CH999 was transformed with pSEK4,  
35 identical to pRM5 except for replacement of a 140 bp

*SphI/SalI* fragment within the *act* KR gene by the *SphI/SalI* fragment from pUC19, the resulting strain produced abundant quantities of the aromatic polyketide SEK4 (12). The exact structure of this product is slightly different from desoxyerythrolaccin (Bartel, P.L. et al. *J. Bacteriol.* (1990) 172:4816). However, *in vivo* isotopic labeling studies using 1,2-<sup>13</sup>C<sub>2</sub>-labeled acetate confirmed that the polyketide backbone is derived from 8 acetates. Moreover, the aromatic region of the <sup>1</sup>H spectrum, as well as the <sup>13</sup>C NMR spectrum of this product, are consistent with a tricyclic structure similar to 1, but lacking any ketoreduction (see Table 4).

#### Example 4

#### Construction and Analysis of Hybrid Polyketide Synthases

##### A. Construction of hybrid PKSs including components from *act*, *gra* and *tcm* PKSs

Figure 1A shows the PKSs responsible for synthesizing the carbon chain backbones of actinorhodin (3), granaticin (4), and tetracenomycin (5) (structures shown in Figure 5) which contain homologous putative KS/AT and ACP subunits, as well as the ORF2 product. The *act* and *gra* PKSs also have KRs, lacking in the *tcm* PKS. Corresponding proteins from each cluster show a high degree of sequence identity. The percentage identities between corresponding PKS proteins in the three clusters are as follows: KS/AT: *act/gra* 76, *act/tcm* 64, *gra/tcm* 70; CLF: *act/gra* 60, *act/tcm* 58, *gra/tcm* 54; ACP: *act/gra* 60, *act/tcm* 43, *gra/tcm* 44. The *act* and *gra* PKSs synthesize identical 16-carbon backbones derived from 8 acetate residues with a ketoreduction at C-9 (Figure 6). In contrast, also as shown in Figure 6, the *tcm* polyketide backbone differs in overall carbon chain

length (20 instead of 16 carbons), lack of any ketoreduction, and regiospecificity of the first cyclization, which occurs between carbons 9 and 14, instead of carbons 7 and 12 for *act* and *gra*.

5           In an attempt to generate novel polyketides, differing in a range of properties, as well as to elucidate aspects of the programming of aromatic PKSs, a systematic series of minimal PKS gene clusters, using various permutations of the ORF1 (encoding the KS/AT  
10 subunit), ORF2 (encoding the CLF subunit) and ORF3 (encoding the ACP subunit) gene products from the *act*, *gra* and *tcm* gene clusters were cloned into pRM5 in place of the existing *act* genes, as shown in Table 1. The resulting plasmids were used to transform CH999 as above.

15           Analysis of the products of the recombinant PKSs containing various permutations among the KS/AT, ORF2 product, and ACP subunits of the PKSs (all constructs also containing the *act* KR, cyclase, and dehydratase genes) indicated that the synthases could be  
20 grouped into three categories (Table 1): those that did not produce any polyketide; those that produced compound 1 (in addition to a small amount of 2); and those that produced a novel polyketide 9 (designated RM20) (Figure 6). The structure of 9 suggests that the polyketide  
25 backbone precursor of this molecule is derived from 10 acetate residues with a single ketoreduction at the C-9 position.

          In order to investigate the influence of the *act* KR on the reduction and cyclization patterns of a  
30 heterologous polyketide chain, pSEK15 was also constructed, which included *tcm* ORFs 1-3, but lacked the *act* KR. (The deletion in the *act* KR gene in this construct was identical to that in pSEK4.) Analysis of CH999/pSEK15 showed the 20 carbon chain product, SEK15  
35 (13) which resembled, but was not identical to,

tetracenomycin C or its shunt products. NMR spectroscopy was also consistent with a completely unreduced decaketide backbone (see Table 4).

5 All *act/gra* hybrids produced compound 1, consistent with the identical structures of the presumed actinorhodin and granaticin polyketides. In each case where a product could be isolated from a *tcm/act* hybrid, the chain length of the polyketide was identical to that of the natural product corresponding to the source of  
10 ORF2. This implies that the ORF2 product, and not the ACP or KS/AT, controls carbon chain length. Furthermore, since all polyketides produced by the hybrids described here, except the ones lacking the KR (CH999/pSEK4 and CH999/pSEK15), underwent a single ketoreduction, it can  
15 be concluded that: (i) the KR is both necessary and sufficient for ketoreduction to occur; (ii) this reduction always occurs at the C-9 position in the final polyketide backbone (counting from the carboxyl end of the chain); and (iii) while unreduced polyketides may  
20 undergo alternative cyclization patterns, in nascent polyketide chains that have undergone ketoreduction, the regiochemistry of the first cyclization is dictated by the position of the resulting hydroxyl, irrespective of how this cyclization occurs in the non-reduced product.  
25 In other words, the *tcm* PKS could be engineered to exhibit new cyclization specificity by including a ketoreductase.

A striking feature of RM20 (9) is the pattern of cyclizations following the first cyclization.  
30 Isolation of mutactin (6) from an *actVII* mutant suggested that the *actVII* product and its *tcm* homolog catalyze the cyclization of the second ring in the biosynthesis of actinorhodin (3) and tetracenomycin (5), respectively (Sherman, D.H. et al. *Tetrahedron* (1991) 47:6029;

35



Summers, R.G. et al. *J. Bacteriol.* (1992) 174:1810). The cyclization pattern of RM20 (9) is different from that of 1 and tetracenomycin F1, despite the presence of the actVII gene on pRM20 (9). It therefore appears that the act cyclase cannot cyclize longer polyketide chains.

Unexpectedly, the strain containing the minimal *tcm* PKS alone (CH999/pSEK33) produced two polyketides, SEK15 (13) and SEK15b (16), as depicted in Figure 8, in approximately equal quantities. Compounds (13) and (16) were also isolated from CH999/pSEK15, however, greater quantities of compound (13) were isolated this construct than of compound (16).

SEK15b is a novel compound, the structure of which was elucidated through a combination of NMR spectroscopy, sodium [1,2-<sup>13</sup>C<sub>2</sub>] acetate feeding experiments and mass spectroscopy. Results from <sup>1</sup>H and <sup>13</sup>C NMR indicated that SEK15b consisted of an unreduced anthraquinone moiety and a pyrone moiety. Sodium [1,2-<sup>13</sup>C<sub>2</sub>]-acetate feeding experiments confirmed that the carbon chain of SEK15b was derived from 10 acetate units. The coupling constants calculated from the <sup>13</sup>C NMR spectrum of the enriched SEK15b sample facilitated peak assignment. Fast atom bombardment (FAB) mass spectroscopy gave a molecular weight of 381 (M + H<sup>+</sup>), consistent with C<sub>20</sub>H<sub>12</sub>O<sub>8</sub>. Deuterium exchange was used to confirm the presence of each hydroxyl in SEK15b.

In order to identify the degrees of freedom available in vivo to a nascent polyketide chain for cyclizing in the absence of an active cyclase, polyketides produced by recombinant *S. coelicolor* CH999/pRM37 (McDaniel et al. (1993), *supra*) were analyzed. The biosynthetic enzymes encoded by pRM37 are the *tcm* ketosynthase/acyltransferase (KS/AT), the *tcm* chain length determining factor (CLF), the *tcm* acyl carrier protein (ACP), and the act ketoreductase (KR).

Two novel compounds, RM20b (14) and RM20c (15) (Figure 8) were discovered in the culture medium of CH999/pRM37, which had previously yielded RM20 (9). The relative quantities of the three compounds recovered were 3:7:1 (RM20:RM20b:RM20c). The structures of (14) and (15) were elucidated through a combination of mass spectroscopy, NMR spectroscopy and isotope labeling experiments.  $^1\text{H}$  and  $^{13}\text{C}$  NMR spectra suggested that RM20b and RM20c were diastereomers, each containing a pyrone moiety. Optical rotations ( $[\alpha]_D^{20}$ ) were found to be +210.8° for RM20b (EtOH, 0.55%) and +78.0° for RM20c (EtOH, 0.33%). Sodium  $[1,2-^{13}\text{C}_2]$ -acetate feeding experiments confirmed that the carbon chain of RM20b (and by inference RM20c) was derived from 10 acetate units. Deuterium exchange studies were carried out in order to identify  $^1\text{H}$  NMR peaks corresponding to potential hydroxyl groups on both RM20b and RM20c. Proton coupling constants were calculated from the results of  $^1\text{H}$  NMR and one-dimensional decoupling experiments. In particular, the coupling pattern in the upfield region of the spectrum indicated a 5-proton spin system of two methylene groups surrounding a central carbinol methine proton. High resolution fast atom bombardment (FAB) mass spectroscopy gave molecular weights of (519.0056) ( $M = \text{Cs}^+$ ) for RM20b and 387.1070 ( $M + \text{H}^+$ ) for RM20c, which is consistent with  $\text{C}_{20}\text{H}_{18}\text{O}_8$  ( $M + \text{Cs}^+$ , 519.0056;  $M + \text{H}^+$ , 387.1080). Based on these data, structures (14) and (15) (Figure 8) were assigned to RM20b and RM20c, respectively.

Data from  $^1\text{H}$  and  $^{13}\text{C}$  NMR indicated that the coupling constants between H-9 and the geminal protons on C-8 were 12.1 or 12.2 and 2.5 or 2.2 Hz for RM20b or RM20c, respectively. The coupling constants between H-9 and the geminal protons on C-10 were 9.6 or 9.7 and 5.7 or 5.8 Hz for RM20b or RM20c, respectively. These values

are typical of a  $J_{a,a}$  ( $J_{9a,8a}$  or  $J_{9a,10a}$ ) and  $J_{a,e}$  ( $J_{9a,8e}$  or  $J_{9a,10e}$ ) coupling pattern, and indicate an axial position for H-9 in both RM20b and RM20c. In contrast, the chemical shifts of the C-7 hydroxyls on the two molecules were 16.18 and 6.14 ppm for RM20b and RM20c, respectively. These values indicate a hydrogen bond between the C-7 hydroxyl and a suitably positioned acceptor atom in RM20b, but not in RM20c. The most likely candidate acceptor atoms for such hydrogen bonding are the C-13 carbonyl oxygen in the conjugated pyrone ring system, or the bridge oxygen in the isolate pyrone ring. The former appears to be likely as it would be impossible to discriminate between (14) and (15) if the latter were the case. Furthermore, comparison of  $^{13}\text{C}$  NMR spectra of RM20b and RM20c revealed that the greatest differences between (14) and (15) were in the chemical shifts of the carbons that make up the conjugated pyrone ring (+5.9, -6.1, +8.9, -7.8 and +2.0 ppm for C-11, C-12, C-13, C-14 and C-15, respectively). Such a pattern of alternating upfield and downfield shifts can be explained by the fact that the C-7 hydroxyl is hydrogen-bonded to the C-13 carbonyl, since hydrogen bonding would be expected to reduce the electron density around C-11, C-13 and C-15, but increase the electron density around C-12 and C-14. To confirm the C-7/C-13 hydrogen bond assignment, the exchangeable protons RM20b and RM20c were replaced with deuterium (by incubating in the presence of  $\text{D}_2\text{O}$ ), and the samples were analyzed by  $^{13}\text{C}$  NMR. The C-13 peak in RM20b, but not RM20c, underwent an upfield shift (1.7 ppm), which can be explained by a weaker C-7/C-13 non-covalent bond in RM20b when hydrogen is replaced with deuterium. In order to form a hydrogen bond with the C-13 carbonyl, the C-7 hydroxyl of RM20b must occupy the equatorial position. Thus, it can be inferred that the C-7 and C-9 hydroxyls are on the same face (syn) of the

conjugated ring system in the major isomer (RM20b), whereas they are on opposite sides (*anti*) in the minor isomer (RM20c).

No polyketide could be detected in CH999/pRM15, /pRM35, and /pRM36. Thus, only some ORF1-ORF2 combinations are functional. Since each subunit was functional in at least one recombinant synthase, protein expression/folding problems are unlikely to be the cause. Instead, imperfect or inhibitory association between the different subunits of these enzyme complexes, or biosynthesis of (aborted) short chain products that are rapidly degraded, are plausible explanations.

B. Construction of hybrid PKSs including components from act and fren PKSs

*Streptomyces roseofulvus* produces both frenolicin B (7) (Iwai, Y. et al. *J. Antibiot.* (1978) 31:959) and nanaomycin A (8) (Tsuzuki, K. et al. *J. Antibiot.* (1986) 39:1343). A 10 kb DNA fragment (referred to as the *fren* locus hereafter) was cloned from a genomic library of *S. roseofulvus* (Bibb, M.J. et al. submitted) using DNA encoding the KS/AT and KR components of the act PKS of *S. coelicolor* A3(2) as a probe (Malpartida, F. et al. *Nature* (1987) 325:818). (See Figure 7 for structural representations.) DNA sequencing of the *fren* locus revealed the existence of (among others) genes with a high degree of identity to those encoding the act KS/AT, CLF, ACP, KR, and cyclase.

To produce the novel polyketides, the ORF1, 2 and 3 act genes present in pRM5 were replaced with the corresponding *fren* genes, as shown in Table 2. *S. coelicolor* CH999, constructed as described above, was transformed with these plasmids. (The genes encoding the act KR, and the act cyclase were also present on each of these genetic constructs.) Based on results from similar

experiments with act and tcm PKSs, described above, it was expected that the act KR would be able to reduce the products of all functional recombinant PKSs, whereas the ability of the act cyclase to catalyze the second  
5 cyclization would depend upon the chain length of the product of the fren PKS.

The results summarized in Table 2 indicate that most of the transformants expressed functional PKSs, as assayed by their ability to produce aromatic polyketides.  
10 Structural analysis of the major products revealed that the producer strains could be grouped into two categories: those that synthesized compound 1 (together with a smaller amount of its decarboxylated side-product (2), and those that synthesized a mixture of compounds 1,  
15 10 and 11 in a roughly 1:2:2 ratio. (Small amounts of 2 were also found in all strains producing 1.) Compounds 1 and 2 had been observed before as natural products, and were the metabolites produced by a PKS consisting entirely of act subunits, as described in Example 3.  
20 Compounds 10 and 11 (designated RM18 and RM18b, respectively) are novel structures whose chemical synthesis or isolation as natural products has not been reported previously.

The structures of 10 and 11 were elucidated  
25 through a combination of mass spectroscopy, NMR spectroscopy, and isotope labeling experiments. The  $^1\text{H}$  and  $^{13}\text{C}$  spectral assignments are shown in Table 3, along with  $^{13}\text{C}$ - $^{13}\text{C}$  coupling constants for 10 obtained through sodium  $[1,2-^{13}\text{C}_2]$  acetate feeding experiments (described  
30 below). Unequivocal assignments for compound 10 were established with 1D nuclear Overhauser effect (NOE) and long range heteronuclear correlation (HETCOR) studies. Deuterium exchange confirmed the presence of hydroxyls at C-15 of compound 10 and C-13 of compound 11. Field  
35 desorption mass spectrometry (FD-MS) of 2 revealed a

molecular weight of 282, consistent with  $C_{17}H_{14}O_4$  (282.2952).

Earlier studies showed that the polyketide backbone of 2 (Bartel, P.L. et al. *J. Bacteriol.* (1990) 172:4816) (and by inference, 1) is derived from iterative condensations of 8 acetate residues with a single ketoreduction at C-9. It may also be argued that nanaomycin (8) arises from an identical carbon chain backbone. Therefore, it is very likely that nanaomycin is a product of the *fren* PKS genes in *S. roseofulvus*. Regiospecificity of the first cyclization leading to the formation of 1 is guided by the position of the ketoreduction, whereas that of the second cyclization is controlled by the act cyclase (Zhang, H.L. et al. *J. Org. Chem.* (1990) 55:1682).

In order to trace the carbon chain backbone of RM18 (10), *in vivo* feeding experiments using  $[1,2-^{13}C_2]$  acetate were performed on CH999/pRM18, followed by NMR analysis of labelled RM18 (10). The  $^{13}C$  coupling data (summarized in Table 3) indicate that the polyketide backbone of RM18 (10) is derived from 9 acetate residues, followed by a terminal decarboxylation (the C-2  $^{13}C$  resonance appears as an enhanced singlet), which presumably occurs non-enzymatically. Furthermore, the absence of a hydroxyl group at the C-9 position suggests that a ketoreduction occurs at this carbon. Since these two features would be expected to occur in the putative frenolicin (7) backbone, the results suggest that, in addition to synthesizing nanaomycin, the *fren* PKS genes are responsible for the biosynthesis of frenolicin in *S. roseofulvus*. This appears to be the first unambiguous case of a PKS with relaxed chain length specificity. However, unlike the putative backbone of frenolicin, the C-17 carbonyl of RM18 (10) is not reduced. This could either reflect the absence from pRM18 of a specific

ketoreductase, dehydratase, and an enoylreductase (present in the *fren* gene cluster in *S. roseofulvus*), or it could reflect a different origin for carbons 15-18 in frenolicin.

5                   Regiospecificity of the first cyclization leading to the formation of RM18 (10) is guided by the position of the ketoreduction; however the second cyclization occurs differently from that in 7 or 1, and is similar to the cyclization pattern observed in RM20  
10 (9), a decaketide produced by the *tcm* PKS, as described above. Therefore, as in the case of RM20 (9), it could be argued that the *act* cyclase cannot catalyze the second cyclization of the RM18 precursor, and that its subsequent cyclizations, which presumably occur  
15 non-enzymatically, are dictated by temporal differences in release of different portions of the nascent polyketide chain into an aqueous environment. In view of the ability of CH999/pRM18 (and CH999/pRM34) to produce 1, one can rule out the possibility that the cyclase  
20 cannot associate with the *fren* PKS (KS/AT, CLF, and ACP). A more likely explanation is that the *act* cyclase cannot recognize substrates of altered chain lengths. This would also be consistent with the putative biosynthetic scheme for RM20 (9).

25                   A comparison of the product profiles of the hybrid synthases reported in Table 2 with analogous hybrids between *act* and *tcm* PKS components (Table 1) support the hypothesis that the ORF2 product is the chain length determining factor (CLF). Preparation of  
30 compounds 9, 10 and 11 via cyclization of enzyme-bound ketides is schematically illustrated in Figure 8.

Example 5The Role of *tcmJ* and *tcmN* in Polyketide Synthesis

To evaluate the specific catalytic roles of the PKS enzymes encoded by *tcmJ* and *tcmN*, *tcmJ* and *tcmN* were expressed in the presence of additional *act* and *tcm* PKS components in the *S. coelicolor* CH999 host-vector system described in Examples 1 through 3. The isolation of three novel polyketides from these genetic constructs has allowed the assignment of two distinct catalytic functions to *tcmN*.

The series of recombinant gene clusters shown in Table 5 was constructed. Each plasmid contained either *tcmJ*, *tcmN*, or both in addition to the minimal PKS genes responsible for the biosynthesis of 16 (*act*) or 20 (*tcm*) carbon backbones. Half of the plasmids also contained the gene encoding the *act* ketoreductase (KR, *actIII*), which catalyzes ketoreduction at the C-9 position of the nascent polyketide backbone. The plasmids were introduced by transformation into *S. coelicolor* CH999. The major polyketides produced by the transformed strains were isolated and structurally characterized using a combination of NMR, isotopic labelling and mass spectroscopy experiments. All of the polyketides isolated have been previously structurally characterized with the exception of the novel polyketides RM77 (19) (Figure 14), RM80 (20), and RM80b (21) (Figure 15).

A comparative analysis of the cyclization patterns of these molecules, together with those reported earlier, reveals two functions for *tcmN*. The first can be illustrated by differences in the proposed pathways for RM77 (19; produced by the *act* minimal PKS + *tcmN*; pRM77) and SEK4 (12; produced by the *act* minimal PKS alone; pSEK24). As shown in Figure 14, *tcmN* influences the regiospecificity of the cyclization of the first



ring. In SEK4 (12), an intramolecular aldol condensation occurs between the C-7 carbonyl and the C-12 methylene. In contrast, a similar reaction occurs between the C-9 carbonyl and the C-14 methylene in RM77 (19); this  
5 represents a shift of one acetate unit in the polyketide backbone. Thus, while earlier results indicated that the course of this reaction is primarily controlled by the minimal PKS, RM77 (19) clearly illustrates the effect of tcmN on the act minimal PKS, which otherwise exclusively  
10 catalyzes C-7/C-12 cyclizations in the absence of tcmN. The absence of any significant amount of SEK15 (13) or other C-7/C-12 cyclized molecules in CH999/pRM80 and CH999/pRM81 also supports the conclusion that  
15 regiospecificity of the first aldol condensation can be controlled by enzymes downstream of the minimal PKS.

An important consequence of the designation the tcmN function is the temporal relationship between the catalytic ketoreduction and cyclization of the first ring. In all naturally occurring and recombinant  
20 polyketides undergoing a C-9 ketoreduction studied to date, initial cyclization occurs between carbons 7 and 12. Therefore, the inability of strains expressing tcmN to produce significant quantities of a polyketide with a C-9/C-14 cyclization in the presence of the act KR  
25 (pRM71, pRM72, pRM74, pRM75; Table 5) indicates that ketoreduction occurs prior to formation of the first ring (Figure 14).

The second function of tcmN is apparent from comparison between the proposed cyclization pathways of  
30 RM80 (20; produced by the tcm minimal PKS + tcmN; pRM80) and SEK15b (16; produced by the tcm minimal PKS alone; pSEK33). Production of these two molecules is mutually exclusive in these strains. As seen in Figure 15, the regiospecificities of the first and second intramolecular  
35 aldol condensations in both molecules are identical.

However, in SEK15b (16) the third ring forms via an aldol condensation between C-6 and C-19, whereas in RM80 (20) it forms via hemiketalization between C-15 and C-19. The difference in these two cyclization pathways can be attributed to enolization of the C-15 carbonyl in RM80 (20), but not in SEK15b (16). This is reminiscent of the related polyketides SEK34 (22) and mutactin (6), shunt products from the early stages of actinorhodin biosynthesis which led to the hypothesis that the act aromatase (ARO) catalyzes the enolization of the C-11 carbonyl. Therefore, it is not surprising that tcmN, a homolog of the act ARO, should catalyze the same reaction; however, the specificities of the two proteins differ. Whereas the act ARO acts on the first ring, tcmN appears to act on the second ring.

TcmN provides an additional tool for the design and biosynthesis of novel polyketides through the genetic manipulation of PKSs. RM77 (19) represents the first example of a 16-carbon polyketide with an engineered first cyclization different from that of the expected "natural" one. Therefore, it is likely that other heterologous PKS complexes containing tcmN (or homologs) along with various minimal PKSs will produce polyketides of different chain length with the alternative first cyclization. This biosynthetic degree of freedom may be limited to unreduced molecules.

#### Example 6

##### Rationally Designed Aromatic Polyketides

All identified gene clusters for actinomycete aromatic polyketides contain a set of three genes encoding a so-called 'minimal PKS' which consists of a ketosynthase (KS), which also carries a putative acyltransferase (AT) domain, a chain length factor (CLF), and an acyl carrier protein (ACP) (Figure 1). A

16-carbon molecule, for example SEK4 (12), can be synthesized from the act minimal PKS alone. In order to produce the C-9 reduced analogue of SEK4, SEK34 (22) (Figure 16), two additional activities are needed: a  
5 ketoreductase (KR) and an aromatizing subunit (ARO) (compare the genes present on pSEK24 and pSEK34; Table 6). The following experiments were designed to determine whether analogous pairs of molecules could be generated from backbones of alternative chain length, for example,  
10 20 carbons using a suitable combination of a minimal PKS, a KR, and an ARO.

The *tcm* minimal PKS (on pSEK33; Table 6) is both necessary and sufficient for synthesis of an unreduced 20 carbon backbone (McDaniel, R. et al. *Proc. Natl. Acad. Sci. USA* (1994) 91:11542-11546), which forms  
15 SEK15 (13). In addition, the act KR can reduce the C-9 carbonyl on such a backbone to a hydroxyl, which is subsequently lost upon spontaneous aromatization of the first carbocyclic ring (Fu, H. et al. *J. Am. Chem. Soc.* (1994) 116:4166-4170). Aromatization of the reduced  
20 ring, in contrast, requires an ARO (McDaniel, R. et al. *J. Am. Chem. Soc.* (1994) 116:10855-10859). However, the act ARO cannot aromatize 20-carbon chains (McDaniel, R., et al. *Science* (1994) 262:1546-1550; McDaniel et al.  
25 *Proc. Natl. Acad. Sci. USA* (1994), *supra*). Furthermore, the *tcm* PKS cluster (which lacks a KR gene) does not appear to encode a first ring ARO which would be a suitable candidate. Accordingly, an ARO gene homologous to the one in the act cluster was chosen from the gene  
30 cluster that encodes the PKS for the 20-carbon polyketide griseusin (*gris*) (Yu, T.-W. et al. *J. Bacteriol.* (1994) 176:2627-2534).

The plasmid pSEK43 (Table 6), containing the *tcm* minimal PKS, the act KR, and the *gris* ARO, was  
35 constructed and introduced into the CH999 host. Analysis

of the transformed strain revealed the anticipated polyketide SEK43 (23), whose structure was determined by NMR, mass spectroscopy, and isotopic labelling studies.

The biosynthesis of SEK43 (23) (Figure 17) reaffirms the conclusion that the act ARO and its homologues aromatize the first ring (McDaniel et al. *J. Am. Chem. Soc.* (1994), *supra*). Without a functional ARO, the *tcm* minimal PKS and act KR (pSEK23; Table 6) produce RM20b (14) (Figure 16), which contains a non-aromatized first ring. Replacement of the *tcm* minimal PKS in pSEK43 with either the act or *fren* minimal PKSs (pSEK41 and pSEK42; Table 6) resulted in production of the 16-carbon aromatized compound SEK34 (22), demonstrating that the *gris* ARO can also recognize shorter carbon chains. It was unexpected, however, that a corresponding 18-carbon polyketide was not detected in the construct containing the *fren* minimal PKS, which has been shown to synthesize both 18- and 16-carbon chains (McDaniel et al. *J. Am. Chem. Soc.* (1993), *supra*). This is probably due to decomposition of the molecule, since CH999/pSEK42 produced small quantities of an uncharacterized molecule not present in CH999/pSEK34. More significantly, evidence for an aromatized 18-carbon intermediate is described below.

A second test of the concept of rational design arose from the previous isolation of the 16-carbon polyketide DMAC (28) (Figure 16). The PKS subunits required for DMAC (28) biosynthesis are a "16-carbon" minimal PKS, a KR, and suitable ARO and CYC components (pRM5; Table 6). CYC catalyzes cyclization of the second ring between carbons 4 and 15, leading eventually to the formation of an anthraquinone (McDaniel et al. *J. Am. Chem. Soc.* (1994), *supra*). These observations suggested that an analogous anthraquinone, with 18 carbons, could be generated. To achieve this, the plasmid pSEK26 (Table

6) containing the *fren* minimal PKS with the *act* KR, the *fren* ARO, and the *act* CYC was constructed. The *fren* minimal PKS and *act* KR were selected for their ability to produce an 18-carbon, C-9 reduced backbone (McDaniel et al. *J. Am. Chem. Soc.* (1993), *supra*; McDaniel et al. *Proc. Natl. Acad. Sci. USA* (1994), *supra*). The *fren* ARO was chosen since the *act* ARO cannot aromatize 18-carbon chains (McDaniel et al. *J. Am. Chem. Soc.* (1993), *supra*; McDaniel et al. *Proc. Natl. Acad. Sci. USA* (1994), *supra*).

Introduction of the plasmid into CH999 resulted in the production of both DMAC (28) and SEK26 (24). The latter is a novel 18-carbon anthraquinone whose structure was confirmed by NMR, mass spectroscopy, and isotopic labelling studies. Formation of SEK26 (24) (Figure 17) occurs through a second ring cyclization at C5/C14 presumably catalyzed by the *act* CYC. The production also of DMAC (28) is consistent with the relaxed chain length specificity of the *fren* minimal PKS (McDaniel et al. *J. Am. Chem. Soc.* (1993), *supra*).

In order to evaluate further the specificity of ARO and CYC subunits towards carbon chains of various lengths, several other PKS combinations were constructed (Table 6). For example, pSEK25 and pSEK26 demonstrate that the *fren* ARO can aromatize both 16- and 18-carbon chains. However, the *fren* ARO cannot handle 20-carbon chains; instead the combination of the *fren* ARO with the *tcm* minimal PKS, *act* KR, and *act* CYC (pSEK27) resulted in biosynthesis of RM20b (14), the non-aromatized 20-carbon polyketide (Figure 16). As expected, replacing the *fren* ARO with the *gris* ARO (pRM51) in pSEK26 yielded DMAC (28) and SEK26 (24). However, attempts to generate a 20-carbon reduced polyketide with a C-5/C-14 second ring cyclization were unsuccessful; replacing the *fren* minimal PKS in pRM51 with the *tcm* minimal PKS (pRM52) resulted in

production of SEK43 (23), indicating that the act CYC cannot cyclize 20-carbon chains. Finally, the plasmids pSEK44-47, pRM51, and pRM52 (Table 6), all lacking KRs, failed to cause production of polyketides different from those produced by the minimal PKS alone (McDaniel et al. *Proc. Natl. Acad. Sci. USA* (1994), *supra*), despite the presence of ARO and CYC components. This is consistent with previous observations that ARO and CYC subunits do not alter the biosynthetic pathways of unreduced polyketides (McDaniel et al. *Proc. Natl. Acad. Sci. USA* (1994), *supra*; Fu, H., McDaniel, R., Hopwood, D.A. & Khosla, C. *Biochemistry* 33:9321-9326 (1994)).

#### Example 7

#### 15 Construction and Analysis of Modular Polyketide Synthases

Expression plasmids containing recombinant modular DEBS PKS genes were constructed by transferring DNA incrementally from a temperature-sensitive "donor" plasmid, i.e., a plasmid capable of replication at a first, permissive temperature and incapable of replication at a second, non-permissive temperature, to a "recipient" shuttle vector via a double recombination event, as depicted in Figure 18. pCK7 (Figure 12), a shuttle plasmid containing the complete *eryA* genes, which were originally cloned from pS1 (Tuan et al. (1990) *Gene* 90:21), was constructed as follows. A 25.6 kb *SphI* fragment from pS1 was inserted into the *SphI* site of pMAK705 (Hamilton et al. (1989) *J. Bacteriol.* 171:4617) to give pCK6 ( $\text{Cm}^R$ ), a donor plasmid containing *eryAII*, *eryAIII*, and the 3' end of *eryAI*. Replication of this temperature-sensitive pSC101 derivative occurs at 30°C but is arrested at 44°C. The recipient plasmid, pCK5 ( $\text{Ap}^R$ ,  $\text{Tc}^R$ ), includes a 12.2 kb *eryA* fragment from the *eryAI* start codon (Caffrey et al. (1992) *FEBS Lett.* 304:225) to the *XcmI* site near the beginning of *eryAII*, a

1.4 kb *EcoRI* - *BsmI* pBR322 fragment encoding the tetracycline resistance gene (*Tc*), and a 4.0 kb *NotI* - *EcoRI* fragment from the end of *eryAIII*. *PacI*, *NdeI*, and ribosome binding sites were engineered at the *eryAI* start codon in pCK5. pCK5 is a derivative of pRM5 (McDaniel et al. (1993), *supra*). The 5' and 3' regions of homology (Figure 18, striped and unshaded areas) are 4.1 kb and 4.0 kb, respectively. MC1061 *E. coli* was transformed (see, Sambrook et al., *supra*) with pCK5 and pCK6 and subjected to carbenicillin and chloramphenicol selection at 30°C. Colonies harboring both plasmids (*Ap*<sup>R</sup>, *Cm*<sup>R</sup>) were then restreaked at 44°C on carbenicillin and chloramphenicol plates. Only cointegrates formed by a single recombination event between the two plasmids were viable. Surviving colonies were propagated at 30°C under carbenicillin selection, forcing the resolution of the cointegrates via a second recombination event. To enrich for pCK7 recombinants, colonies were restreaked again on carbenicillin plates at 44°C. Approximately 20% of the resulting colonies displayed the desired phenotype (*Ap*<sup>R</sup>, *Tc*<sup>S</sup>, *Cm*<sup>S</sup>). The final pCK7 candidates were thoroughly checked via restriction mapping. A control plasmid, pCK7f, which contains a frameshift error in *eryAI*, was constructed in a similar manner. pCK7 and pCK7f were transformed into *E. coli* ET12567 (MacNeil (1988) *J. Bacteriol.* 170:5607) to generate unmethylated plasmid DNA and subsequently moved into *Streptomyces coelicolor* CH999 using standard protocols (Hopwood et al. (1985) *Genetic manipulation of Streptomyces*. A laboratory manual. The John Innes Foundation: Norwich).

Upon growth of CH999/pCK7 on R2YE medium, the organism produced abundant quantities of two polyketides (Figure 20). The addition of propionate (300 mg/L) to the growth medium resulted in approximately a two-fold increase in yield of polyketide product. Proton and <sup>13</sup>C

NMR spectroscopy, in conjunction with propionic-1-<sup>13</sup>C acid feeding experiments, confirmed the major product as 6dEB (17) (> 40 mg/L). The minor product was identified as 8,8a-deoxyoleandolide (18) (> 10 mg/L), which  
5 apparently originates from an acetate starter unit instead of propionate in the 6dEB biosynthetic pathway. <sup>13</sup>C<sub>2</sub> sodium acetate feeding experiments confirmed the incorporation of acetate into (18). Three high molecular weight proteins (>200 kDa), presumably DEBS1, DEBS2, and  
10 DEBS3 (Caffrey et al. (1992) *FEBS Lett.* 304:225), were also observed in crude extracts of CH999/pCK7 via SDS-polyacrylamide gel electrophoresis. No polyketide products were observed from CH999/pCK7f. The inventors hereby acknowledge support provided by the American  
15 Cancer Society (IRG-32-34).

#### Example 8

##### Manipulation of Macrolide Ring Size by Directed Mutagenesis of DEBS

20 In order to investigate the relationship between structure and function in modular PKSs and to apply this knowledge towards the rational and stochastic design of novel polyketides, a host-vector expression system was designed to study DEBS (Kao, C. M. et al.  
25 *Science* (1994) 265:509-512). Using this expression system, the expression of DEBS1 alone, in the absence of DEBS2 and DEBS3, resulted in the production of (2R,3S,4S,5R)-2,4-dimethyl-3,5-dihydroxy-n-heptanoic acid  $\delta$ -lactone ("the heptanoic acid  $\delta$ -lactone" (25)) (1-3  
30 mg/L), the expected triketide product of the first two modules (Figure 21A) (Kao, C. M. et al. *J. Am. Chem. Soc.* (1994) 116:11612-11613). The synthesis of the heptanoic acid  $\delta$ -lactone (25) provided further biochemical evidence for the modular PKS model of Katz and coworkers (Donadio,  
35 S. et al. *Science* (1991), *supra*) and showed that a



thioesterase is not essential for release of a triketide from the enzyme complex.

In this Example the role of the thioesterase (TE) domain in DEBS was analyzed by constructing two additional deletion mutant PKSs that consist of different subsets of the DEBS modules and the TE. The first PKS contained DEBS1 fused to the TE, whereas the second PKS included the first five DEBS modules with the TE; plasmids pCK12 and pCK15 contained the genes encoding the bimodular ("1+2+TE") and pentamodular ("1+2+3+4+5+TE") PKSs.

The 1+2+TE PKS contained a fusion of the carboxy-terminal end of the acyl carrier protein of module 2 (ACP-2) to the carboxy-terminal end of the acyl carrier protein of module 6 (ACP-6). Thus ACP-2 is essentially intact in this PKS and is followed by the amino acid sequence naturally found between ACP-6 and the TE (Figure 21B). Plasmid pCK12 contained *eryA* DNA originating from pS1 (Tuan, J. S. et al. *Gene* (1990) 90:21). pCK12 is identical to pCK7 (Kao et al. *Science* (1994), *supra*) with the exception of a deletion between the carboxy-terminal ends of ACP-2 and ACP-6. The fusion occurs between residues L3455 of DEBS1 and Q2891 of DEBS3. An *SpeI* site is present between these two residues so that the DNA sequence at the fusion is CTCACTAGTCAG.

The 1+2+3+4+5+TE PKS contained a fusion 76 amino acids downstream of the  $\beta$ -ketoreductase of module 5 (KR-5) and five amino acids upstream of ACP-6. Thus, the fusion occurs towards the carboxy-terminal end of the non-conserved region between KR-5 and ACP-5, and the recombinant module 5 was essentially a hybrid between the wild type modules 5 and 6 (Figure 22). Plasmid pCK15 contained *eryA* DNA originating from pS1 (Tuan et al. *Gene* (1990), *supra*). pCK15 is a derivative of pCK7 (Kao et

al. *Science* (1994), *supra*) and was constructed using an  
in vivo recombination strategy described earlier (Kao et  
al. *Science* (1994), *supra*). pCK15 is identical to pCK7  
with the exceptions of a deletion between KR-5 and ACP-6,  
5 which occurs between residues G1372 and A2802 of DEBS3,  
and the insertion of a blunted a *SalI* fragment containing  
a kanamycin resistance gene (Oka A. et al. *J. Mol. Biol.*  
(1981) 147:217) into the blunted *HindIII* site of pCK7.  
An arginine residue is present between G1372 and A2802 so  
10 that the DNA sequence at the fusion is GGCCGCGCC.

Plasmids pCK12 and pCK15 were introduced into  
*S. coelicolor* CH999 and polyketide products purified from  
the transformed strains according to methods previously  
described (Kao et al. *Science* (1994), *supra*).

15 CH999/pCK12 produced the heptanoic acid  
 $\delta$ -lactone (25) (20 mg/L) as determined by  $^1\text{H}$  and  $^{13}\text{C}$  NMR  
spectroscopy. This triketide product is identical to  
that produced by CH999/pCK9, which expresses the  
unmodified DEBS1 protein alone (Kao *J. Am. Chem. Soc.*  
20 (1994), *supra*. However, CH999/pCK12 produced the  
heptanoic acid  $\delta$ -lactone (25) in significantly greater  
quantities than CH999/pCK9 (>10 mg/L vs. ~1 mg/L),  
indicating the ability of the TE to catalyze thiolysis of  
a triketide chain attached to the ACP domain of module 2.  
25 CH999/pCK12 also produced significant quantities of a  
novel analog of (2*R*,3*S*,4*S*,5*R*)-2,4-dimethyl-3,5-dihydroxy-*n*-  
hexanoic acid  $\delta$ -lactone ("the hexanoic acid  $\delta$ -lactone  
(26)) (10 mg/L), that resulted from the incorporation of  
an acetate start unit instead of propionate. This is  
30 reminiscent of the ability of CH999/pCK7, which expresses  
intact DEBS, to produce 8,8a-deoxyoleandolide (18) in  
addition to 6dEB (17) (Kao et al. *Science* (1994), *supra*).

Since the hexanoic acid  $\delta$ -lactone (26) was not  
detected in CH999/pCK9, its facile isolation from  
35 CH999/pCK12 provides additional evidence for the

increased turnover rate of DEBS1 due to the presence of the TE. In other words, the TE can effectively recognize an intermediate bound to a "foreign" module that is four acyl units shorter than its natural substrate, 6dEB (17).

5 However, since the triketide products can probably cyclize spontaneously into the heptanoic acid  $\delta$ -lactone (25) and the hexanoic acid  $\delta$ -lactone (26) under typical fermentation conditions (pH 7), it is not possible to discriminate between a biosynthetic model involving

10 enzyme-catalyzed lactonization and one involving enzyme-catalyzed hydrolysis followed by spontaneous lactonization. Thus, the ability of the 1+2+TE PKS to recognize the C-5 hydroxyl of a triketide as an incoming nucleophile is unclear.

15 The second recombinant strain, CH999/pCK15, produced abundant quantities of (8R,9S)-8,9-dihydro-8-methyl-9-hydroxy-10-deoxymethonolide ("the 10-deoxymethonolide (27); Figure 22) (10 mg/L), demonstrating that the pentamodular PKS is active. The

20 10-deoxymethonolide (27) was characterized using  $^1\text{H}$  and  $^{13}\text{C}$  NMR spectroscopy of natural abundance and  $^{13}\text{C}$ -enriched material, homonuclear correlation spectroscopy (COSY), heteronuclear correlation spectroscopy (HETCOR), mass spectrometry, and molecular

25 modeling. The 10-deoxymethonolide (27) is an analog of 10-deoxymethonolide (Lambalot, R. H. et al. *J. Antibiotics* (1992) 45:1981-1982), the aglycone of the macrolide antibiotic methymycin. The production of the 10-deoxymethonolide (27) by a pentamodular enzyme

30 demonstrates that active site domains in modules 5 and 6 in DEBS can be joined without loss of activity. If this proves to be a general feature of the multimodular proteins that constitute modular PKSS, then any structural model for module assembly must account for the

35 fact that individual modules as well as active sites are

independent entities which do not depend on association with neighboring modules to be functional. Most remarkably, the 12-membered lactone ring, formed by esterification of the terminal carboxyl with the C-11 hydroxyl of the hexaketide product, indicated the ability of the 1+2+3+4+5+TE PKS, and possibly the TE itself, to catalyze lactonization of a polyketide chain one acyl unit shorter than the natural product of DEBS, 6dEB (17). Indeed, the formation of the 10-deoxymethonolide (27) may mimic the biosynthesis of the closely related 12-membered hexaketide macrolide, methymycin, which frequently occurs with the homologous 14-membered heptaketide macrolides, picromycin and/or narbomycin (Cane, D. E. et al. *J. Am. Chem. Soc.* (1993) 115:522-566). A modular PKS such as DEBS could thus be used to generate a wide range of macrolactones with shorter as well as longer chain lengths. The latter products would require the introduction of additional heterologous modules into DEBS.

The construction of the 1+2+3+4+5+TE PKS resulted in the biosynthesis of a previously uncharacterized 12-membered macrolactone that closely resembles, but is distinct from, the aglycone of a biologically active macrolide. The apparent structural and functional independence of active site domains and modules as well as relaxed lactonization specificity suggest the existence of many degrees of freedom for manipulating these enzymes to produce new modular PKSs. Libraries of new macrolides can be generated by altering the association of active site domains and entire modules, the subset of reductive domains within each module, the activity of the TE, and possibly even downstream modification reactions such as hydroxylation and glycosylation. Such libraries could prove to be rich sources of new leads for drug discovery

Thus, novel polyketides, as well as methods for  
 5 recombinantly producing the polyketides, are disclosed.  
 Although preferred embodiments of the subject invention  
 have been described in some detail, it is understood that  
 obvious variations can be made without departing from the  
 spirit and the scope of the invention as defined by the  
 10 appended claims.

TABLE 1

	Plasmid	ORF1 (KS/AT)	ORF2 (CLDF)	ORF3 (ACP)	Major Product(s)	Backbone Carbon Length
15	pRM5	<i>act</i>	<i>act</i>	<i>act</i>	1,2	16
	pRM7	<i>gra</i>	<i>act</i>	<i>act</i>	1,2	16
	pRM12	<i>act</i>	<i>gra</i>	<i>act</i>	1,2	16
20	pRM22	<i>act</i>	<i>act</i>	<i>gra</i>	1,2	16
	pRM10	<i>tcm</i>	<i>act</i>	<i>act</i>	1,2	16
	pRM15	<i>act</i>	<i>tcm</i>	<i>act</i>	NP	--
	pRM20	<i>tcm</i>	<i>tcm</i>	<i>act</i>	9	20
25	pRM25	<i>act</i>	<i>act</i>	<i>tcm</i>	1,2	16
	pRM35	<i>tcm</i>	<i>act</i>	<i>tcm</i>	NP	--
	pRM36	<i>act</i>	<i>tcm</i>	<i>tcm</i>	NP	--
	pRM37	<i>tcm</i>	<i>tcm</i>	<i>tcm</i>	9,14,15	20
30	pSEK15	<i>tcm</i>	<i>tcm</i>	<i>tcm</i>	13,16	20
	pSEK33	<i>tcm</i>	<i>tcm</i>	<i>act</i>	13,16	20

Table 3.  $^1\text{H}$ (400 MHz) and  $^{13}\text{C}$ (100 MHz) NMR data from RM18(10) and RM18b(11)

carbon $^{\alpha}$	RM18			RM18b		
	$^{13}\text{C}\delta(\text{ppm})$	$(J_{\text{CC}}(\text{Hz}))$	$^1\text{H}\delta(\text{ppm})$ (m, $J_{\text{HH}}(\text{Hz})$ , area)	carbon $^{\alpha}$	$^{13}\text{C}\delta(\text{ppm})$	$^1\text{H}\delta(\text{ppm})$ (m, $J_{\text{HH}}(\text{Hz})$ , area)
2	29.6	NC <sup>b</sup>	2.2(s, 3H)			
3	203.7	37.7				
4	47.0	36.9	3.6(s, 2H)	2	18.8	2.1(s, 3H)
5	149.6	77.2		3	152.3	
6	106.7	77.4	6.2(s, 1H)	4	104.0	6.1(s, 1H)
7	129.1	61.9		5	130.0	
8	114.4	62.1	6.7(d, 7.2, 1H)	6	113.5	6.7(d, 7.0)
9	130.1	58.9	7.3(dd, 8.4, 7.4, 1H)	7	130.1	7.3(dd, 7.1, 8.7, 1H)
10	120.6	59.2	7.6(d, 8.9, 1H)	8	120.1	7.6(d, 8.6, 1H)
11	132.7	56.0		9	132.8	
12	116.7	55.7		10	116.6	
13	155.6	74.7		11	155.9	
14	98.4	74.9		12	98.2	
15	158.8	69.6	6.4(s, 1H)	13	159.1	6.4(s, 1H)
16	113.6	69.3	11.2(s, 1OH)	14	113.8	11.2(s, 1OH)
17	201.7	41.9		15	201.7	
18	32.4	41.7	2.5(s, 3H)	16	32.4	2.5(s, 3H)

 $^{\alpha}$  carbons are labelled according to their number in the polyketide backbone<sup>b</sup> NC, not coupled

TABLE 2

	Plasmid	ORF1 (KS/AT)	ORF2 (CLDF)	ORF3 (ACP)	Major Product(s)
5	pRM5	<i>act</i>	<i>act</i>	<i>act</i>	1,2
	pRM8	<i>fren</i>	<i>act</i>	<i>act</i>	1,2
	pRM13	<i>act</i>	<i>fren</i>	<i>act</i>	NP
	pRM23	<i>act</i>	<i>act</i>	<i>fren</i>	1,2
10	pRM18	<i>fren</i>	<i>fren</i>	<i>act</i>	1,2,10,11
	pRM32	<i>fren</i>	<i>act</i>	<i>fren</i>	NP
	pRM33	<i>act</i>	<i>fren</i>	<i>fren</i>	NP
	pRM34	<i>fren</i>	<i>fren</i>	<i>fren</i>	0001,2,10, 11

15

20

25

30

35

Table 4.  $^1\text{H}$  and  $^{13}\text{C}$  NMR data for SEK4 (12) and SEK15 (13)<sup>a</sup>

SEK4 (12)					SEK15 (13)				
carbon <sup>b</sup>	$^{13}\text{C}\delta(\text{ppm})$	$J_{\text{CC}}(\text{Hz})$	$^1\text{H}\delta(\text{ppm})$	carbon	$^{13}\text{C}\delta(\text{ppm})$	$J_{\text{CC}}(\text{Hz})$	$^1\text{H}\delta(\text{ppm})$		
1	165.4	78.8	11.60(s, 1OH)	1	164.0	79.1	12.20(s, 1OH)		
2	88.2	79.8	6.26(d, $J=2.28\text{ Hz}$ , 1H)	2	88.2	79.4	6.20(d, $J=1.88\text{ Hz}$ , 1H)		
3	170.5	55.3		3	172.8	57.9			
4	111.3	61.3	6.33(d, $J=2.24\text{ Hz}$ , 1H)	4	101.8	53.9	6.20(d, $J=1.88\text{ Hz}$ , 1H)		
5	163.8	51.0		5	163.1	50.4			
6	37.6	50.8	4.07(d, $J=15.7\text{ Hz}$ , 1H) 4.16(d, $J=16.0\text{ Hz}$ , 1H)	6	36.7	50.8	1.90(s, 2H)		
7	138.6	60.7		7	135.4	60.7			
8	102.9	60.9	5.66(d, $J=1.6\text{ Hz}$ , 1H)	8	109.1	61.7	5.66 (s, 1H)		
9	161.9	71.9	10.50(s, 1OH)	9	159.8	66.2			
10	100.6	70.9	5.19(d, $J=1.96\text{ Hz}$ , 1H)	10	101.6	66.5	5.08 (s, 1H)		



Table 4.  $^1\text{H}$  and  $^{13}\text{C}$  NMR data for SEK4 (12) and SEK15 (13)<sup>a</sup>

SEK4 (12)				SEK15 (13)			
carbon <sup>b</sup>	<sup>13</sup> Cδ(ppm)	J <sub>CC</sub> (Hz)	<sup>1</sup> Hδ(ppm)	carbon	<sup>13</sup> Cδ(ppm)	J <sub>CC</sub> (Hz)	<sup>1</sup> Hδ(ppm)
11	162.9	60.8		11	157.4	67.3	
12	112.9	61.6		12	121.1	67.6	
13	191.1	39.1		13	200.3	58.1	
14	49.3	39.9	2.54(d, J=15.9 Hz, 1H) 4.92(d, J=16.0 Hz, 1H)	14	117.2	58.6	
15	99.6	46.6	6.90(s, 1OH)	15	163.6	68.5	
16	27.5	46.8	1.56(s, 3H)	16	100.6	68.0	6.08 (s, 1H)
				17	162.2	62.6	
				18	111.0	62.0	6.12 (s, 1H)
				19	141.9	43.3	
				20	21.1	42.7	1.86 (s, 3H)

a.  $^1\text{H}$  and  $^{13}\text{C}$  NMR's were recorded in DMSO- $d_6$  (400 MHz for  $^1\text{H}$  and 100 MHz for  $^{13}\text{C}$ )

b. carbons are labelled according to their number in the polyketide backbone

TABLE 5

	Plasmid	Minimal PKS*	KR	<i>tcm</i> J,N	Major Product(s)
5	pSEK21	<i>act</i>	<i>act</i>	--	6
	pRM70	<i>act</i>	<i>act</i>	J	6
	pRM71	<i>act</i>	<i>act</i>	N	6
	pRM72	<i>act</i>	<i>act</i>	J,N	6
10	pSEK23	<i>tcm</i>	<i>act</i>		10
	pRM73	<i>tcm</i>	<i>act</i>	J	10
	pRM74	<i>tcm</i>	<i>act</i>	N	10
	pRM75	<i>tcm</i>	<i>act</i>	J,N	10
15	pSEK24	<i>act</i>	--	--	12
	pRM76	<i>act</i>	--	J	12
	pRM77	<i>act</i>	--	N	19
	pRM78	<i>act</i>	--	J,N	19
20	pSEK33	<i>tcm</i>	--	--	13,16
	pRM79	<i>tcm</i>	--	J	13,16
	pRM80	<i>tcm</i>	--	N	20,21
	pRM81	<i>tcm</i>	--	J,N	20,21

\* The minimal PKS contains the ketosynthase/putative acyl transferase, chain length factor, and *act* acyl carrier protein.

TABLE 6

	Plasmid	Minimal PKS*	KR	ARO	CYC	Major Product
5	pSEK24	<i>act</i>	--	--	--	12
	pSEK34	<i>act</i>	<i>act</i>	<i>act</i>	--	22
	pRM5	<i>act</i>	<i>act</i>	<i>act</i>	<i>act</i>	28
	pSEK33	<i>tcm</i>	--	--	--	13
	pSEK23	<i>tcm</i>	<i>act</i>	--	--	14
10	pSEK41	<i>act</i>	<i>act</i>	<i>gris</i>	--	22
	pSEK42	<i>fren</i>	<i>act</i>	<i>gris</i>	--	22
	pSEK43	<i>tcm</i>	<i>act</i>	<i>gris</i>	--	23
15	pSEK25	<i>act</i>	<i>act</i>	<i>fren</i>	<i>act</i>	28
	pSEK26	<i>fren</i>	<i>act</i>	<i>fren</i>	<i>act</i>	28/24
	pSEK27	<i>tcm</i>	<i>act</i>	<i>fren</i>	<i>act</i>	14
	pRM51	<i>fren</i>	<i>act</i>	<i>gris</i>	<i>act</i>	28/24
	pRM52	<i>tcm</i>	<i>act</i>	<i>gris</i>	<i>act</i>	23
20	pSEK44	<i>act</i>	--	<i>gris</i>	--	12
	pSEK45	<i>tcm</i>	--	<i>gris</i>	--	13
	pSEK46	<i>act</i>	--	<i>fren</i>	<i>act</i>	12
	pSEK47	<i>tcm</i>	--	<i>fren</i>	<i>act</i>	13
25	pRM53	<i>act</i>	--	<i>gris</i>	<i>act</i>	12
	pRM54	<i>tcm</i>	--	<i>gris</i>	<i>act</i>	13

\* The minimal PKS contains the ketosynthase/putative acyl transferase, chain length factor, and *act* acyl carrier protein.

30

35

Claims

1. A method for preparing a combinatorial polyketide library comprising:
- 5 (a) providing a population of vectors wherein the vectors comprise a random assortment of polyketide synthase (PKS) genes, modules, active sites, or portions thereof and one or more control sequences operatively linked to said genes;
- 10 (b) transforming a population of host cells with said population of vectors;
- (c) culturing said population of host cells under conditions whereby the genes in said gene cluster can be transcribed and translated, thereby
- 15 producing a combinatorial library of polyketides.
2. The method of claim 1, wherein the PKS genes are selected from the group consisting of native, homolog and mutant genes.
- 20 3. The method of claim 2, wherein the mutant PKS gene is produced by site-directed mutagenesis, random mutagenesis or recombination-enhanced mutagenesis.
- 25 4. The method of claim 1, wherein the PKS genes are minimal PKS genes.
5. The method of claim 1, wherein the PKS genes are modular PKS genes.
- 30 6. The method of claim 1, wherein the vector further comprises genes encoding post-polyketide synthesis enzymes derived from natural products pathways.

35

7. The method of claim 6, wherein the enzymes are selected from the group consisting of O-methyltransferases and glycosyltransferases.

5           8. The method of claim 4, wherein the minimal PKS genes comprise a random assortment of first genes encoding a PKS ketosynthase and a PKS acyltransferase active site (KS/AT), a random assortment of second genes encoding a PKS chain length determining factor (CLF), and  
10           a random assortment of third gene encoding a PKS acyl carrier protein (ACP).

          9. The method of claim 8, wherein the vectors additionally comprise a random assortment of fourth genes  
15           encoding a PKS ketoreductase (KR).

          10. The method of claim 9, wherein the vectors additionally comprise a random assortment of fifth genes encoding a PKS cyclase (CYC).  
20

          11. The method of claim 9, wherein the vectors additionally comprise a random assortment of fifth genes encoding a PKS aromatase (ARO).

25           12. The method of claim 10, wherein the vectors additionally comprise a random assortment of sixth genes encoding a PKS aromatase (ARO).

          13. The method of any of claims 8-12, wherein  
30           each of said first, second and third genes is contained in a separate expression cassette.

          14. The method of claim 1, wherein the control sequences comprise promoter sequences which result in the  
35           expression of polyketides as secondary metabolites.

15. The method of claim 14, wherein the promoter sequences are derived from a PKS gene cluster.

5 16. The method of claim 15, wherein the PKS gene cluster is selected from the group consisting of the actinorhodin gene cluster, the tetracenomycin gene cluster, and the spiramycin gene cluster.

10 17. A method for producing a combinatorial polyketide library comprising:

15 (a) providing one or more expression plasmids containing a random assortment of 1 or more first modules of a modular PKS gene cluster wherein the expression plasmids express a gene which encodes a first selection marker;

20 (b) providing a pool of donor plasmids containing a random assortment of second modules of a modular PKS gene cluster wherein the donor plasmids express a gene which encodes a second selection marker and further wherein the donor plasmids comprise regions of DNA complementary to regions of DNA in the expression plasmids, such that homologous recombination can occur between the first and second modules;

25 (c) transforming the expression plasmids and the donor plasmids into a first population of host cells to produce a first pool of transformed host cells;

30 (d) culturing the first pool of transformed host cells under conditions which allow homologous recombination to occur between the first and second modules to produce recombined plasmids comprising recombined PKS gene cluster modules;

35 (e) transferring the recombined plasmids into a second population of host cells to generate a second pool of transformed host cells; and

(f) culturing the second pool of transformed host cells under conditions whereby the combinatorial polyketide library is produced.

5           18. The method of claim 17, wherein the donor plasmid is capable of replication at a first, permissive temperature and incapable of replication at a second, non-permissive temperature and the culturing is done at  
10 the first, permissive temperature followed by the second, non-permissive temperature.

          19. The method of claims 17 or 18, wherein steps (a) through (f) are repeated using the recombined plasmids as the expression plasmids.

15

          20. A recombinant vector comprising:

          (a) a DNA sequence comprising a PKS gene cluster; and

          (b) control elements that are operably linked  
20 to said DNA sequence whereby said DNA sequence can be transcribed, translated and functionally expressed in a host cell and at least one of said control elements is heterologous to said nucleotide sequence.

25           21. The vector of claim 20, wherein the PKS gene cluster is a minimal PKS gene cluster.

          22. The vector of claim 20, wherein the PKS gene cluster is a modular PKS gene cluster.

30

          23. The vector of claim 20, wherein the control elements comprise promoter sequences which result in the expression of polyketides as secondary metabolites.

35

24. The vector of claim 23, wherein the promoter sequences are derived from a PKS gene cluster.

5 25. The vector of claim 24, wherein the control sequences comprise promoter sequences that are derived from a PKS gene cluster selected from the group consisting of the actinorhodin gene cluster, the tetracenomycin gene cluster, and the spiramycin gene cluster.

10

26. The plasmid pCK7.

27. A host cell transformed with the vector of any of claims 20-25.

15

28. A host cell transformed with the plasmid of claim 26.

20 29. The recombinant host cell of claim 27, wherein the PKS gene cluster is a minimal PKS gene cluster comprising a first gene encoding a PKS ketosynthase and a PKS acyltransferase active site (KS/AT), a second gene encoding a PKS chain length determining factor (CLF), and a third gene encoding a PKS  
25 acyl carrier protein (ACP).

30. The recombinant host cell of claim 29, wherein the replacement PKS gene cluster further comprises a gene encoding a PKS ketoreductase (KR).

30

31. The recombinant host cell of claim 30, wherein the replacement PKS gene cluster further comprises a gene encoding a PKS cyclase (CYC).

35



32. The recombinant host cell of claim 30, wherein the replacement PKS gene cluster further comprises a gene encoding a PKS aromatase (ARO).

5           33. The recombinant host cell of claim 31, wherein the replacement PKS gene cluster further comprises a gene encoding a PKS aromatase (ARO).

10           34. The recombinant host cell of claim 27, wherein host cell further comprises genes encoding post-polyketide synthesis enzymes derived from natural products pathways.

15           35. The recombinant host cell of claim 34, wherein the enzymes are selected from the group consisting of O-methyltransferases and glycosyltransferases.

20           36. A method for producing a recombinant polyketide comprising:

            (a) providing a population of host cells according to any of claims 27-35; and

            (b) culturing the population of cells under conditions whereby the replacement PKS gene cluster  
25           present in the cells, is expressed.

30

35

1 / 25




FIG. 1A




FIG. 1B




FIG. 2A




FIG. 2B





FIG. 2C

**FIG. 3**







FIG. 4




Actinorhodin (3)



Granaticin (4)




Tetracenomycin F1 (5)



Mutactin (6)


**FIG. 5**




**FIG. 6**

R-H Aloesaponarin II (2)  
-COOH 3,8-dihydroxy-1-methylanthraquinone-2-carboxylic acid (1)




**FIG. 7**


9 / 25



10 / 25




SEK4 (12)




SEK15 (13)

FIG. 8A


11 / 25



RM20b (14)



RM20c (15)



SEK15b (16)

**FIG. 8B**  
SUBSTITUTE SHEET (RULE 26)

12 / 25





FIG. 9

**FIG. 10**

14 / 25




FIG. II

**FIG. 12**






FIG. 13A




FIG. 13B




FIG. 13C




FIG. 13D










FIG. 13E




















19 / 25

**SEK34 (22)***(act mlnPKS, act KR, act ARO)***SEK43 (23)***(tcm mlnPKS, act KR, grls ARO)***DMAC (28)***(mlnPKS, KR, ARO, CYC; all act)***SEK26 (24)***(tcm mlnPKS, act KR, fren ARO, act CYC)***FIG. 16**



SEK43 (23)



SEK26 (24)

FIG. 17  
SUBSTITUTE SHEET (RULE 26)

21 / 25


Ap<sup>R</sup>, Cm<sup>R</sup> @ 30°CAp<sup>R</sup>, Cm<sup>R</sup> @ 44°CAp<sup>R</sup> @ 30°CAp<sup>R</sup>, Cm<sup>S</sup>, Tc<sup>S</sup> @ 44°C

FIG. 18

22 / 25








FIG. 19

23 / 25



(17)




(18)


FIG. 20

SUBSTITUTE SHEET (RULE 26)






**FIG. 2IA**



**FIG. 2IB**

25 / 25



(27)  
**FIG. 22**

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US96/09320

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :C12P 7/26; C12N 5/00, 11/00, 15/63

US CL :435/148, 240.1, 243, 320.1

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/148, 240.1, 243, 320.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	FU et al. Engineered biosynthesis of novel polyketides: stereochemical course of two reactions catalyzed by polyketide synthase. Biochemistry. 1994, Vol. 33, No. 31, pages 9321-9326. See abstract.	1-36
X	MCDANIEL et al. Engineered biosynthesis of novel polyketides. Science. 03 December 1993, Vol. 262, pages 1546-1550. See abstract.	1-36
X	ROHR, J. Combinatorial biosynthesis-an approach in the near future? Angew. Chem. Int. Ed. Engl. 02 May 1995, Vol. 34, No. 8, pages 881-885. The entire article.	1-36



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E* earlier document published on or after the international filing date	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z*	document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means		
*P* document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

23 AUGUST 1996

Date of mailing of the international search report

09 SEP 1996

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

NASHAAT NASHED

Telephone No. (703) 308-0196

## INTERNATIONAL SEARCH REPORT

 International application No.  
 PCT/US96/09320

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Database Caplus on STN, Chemical Abstract, No. 123:169385, TSOI et al. Combinatorial biosynthesis of unnatural and natural products: the polyketide example. Chem. Biol. 1995, Vol. 2, No. 6, pages 355-362. See abstract.	1-36
Y	HUTCHINSON, C. H. Drug synthesis by genetically engineered microorganisms. Bio/Technology. 12 April 1994, Vol. 12, pages 375-380. See right column on page 376 to the end of the first paragraph, right column on page 378, also see the perspective on 379, the last third of the left column.	1-36
Y	KHOSLA et al. Targeted gene replacements in a <i>streptomyces</i> polyketide synthase gene cluster: role for the acyl carrier protein. Molecular Microbiology. 1992, Vol. 6, No. 21, pages 3237-3249. See discussion section on pages 3245-3246.	1-36
Y	STROHL et al. Expression of polyketide biosynthesis and regulatory genes in heterologous streptomycetes. J. Ind. Microbiol. 1991, Vol. 7, pages 163-174. See in particularly page 165, right column.	1-36
A, P	GORDON et al. Strategy and tactics in combinatorial organic synthesis. Application to drug discovery. Acc. Chem. Res. 1996, Vol. 29, No. 3, pages 144-154.	1-19
Y	US 4,935,340 A (BALTZ ET AL.) 19 June 1990, the claims in columns 25 and 26.	20-36
Y	STROHL et al. Significance of anthraquinone formation resulting from the cloning of actinorhodin genes in heterologous streptomycetes. Molecular Microbiology. 1992, Vol. 6, No. 2, pages 147-152. See page 150, last paragraph of the left column through page 151, left paragraph, the first two third of the left column.	1-36
Y	MCALPINE et al. New antibiotics from genetically engineered actinomycetes. I. 2-Norerythromycins, isolation and structural determinations. The Journal of Antibiotics. August 1987, Vol. 40, No. 8, pages 1115-1122. See abstract and the following three paragraphs on page 1115.	20-25 and 27-35

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US96/09320

## B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

APS, STN: Medline, Caplus, Scisearch, Lifesci, Biosis, Wpids, and Biotechds

Terms: polyketide, biosynthesis, enzyme, genes, combinatorial, drug discovery.